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Abstract 
 
A novel controlled release delivery system has been formulated using natural silk proteins 
extracted from cocoons of silkworms. The benefits of using silk fibroin, the major protein in 
silk, has been widely established in many applications, however this is the first time to report 
silk fibroin as being formulated and tested for pulmonary drug delivery. Silk fibroin particles 
were formulated and engineered for efficient delivery to the airways via dry powder inhalers 
and demonstrated high aerosolisation performance through the measurement of in vitro lung 
deposition. Various drugs were incorporated into the silk particles, and ultimately silk 
particles were loaded with cisplatin to develop controlled-release drug delivery systems that 
target lung cancer. Human lung epithelial cell line was used to test cytocompatibility of silk 
particles and the cytotoxicity of silk-cisplatin particles with normal or cross-linked silk 
formulations. Positive results were obtained and contributed for the optimisation of silk-based 
controlled-release delivery systems for pulmonary drug delivery.  
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I. Inroduction 
 
1. Background 
Silk has been used for centuries as fabric as well as in cosmeceutics, and is recently attracting 
immense attention in biomedical applications (1). Silk has been used as surgical sutures for 
decades due to its biocompatibility and outstanding mechanical properties exemplified by 
toughness that is two to three times higher than synthetic fibres like Nylon or Kevlar (2). In 
addition to these qualities, silk is known for properties including controllable biodegradability, 
superior mechanical strength and stability, elasticity, biocompatibility and uncomplicated 
processing procedures (1). These properties make silk a superior material when compared to 
other polymers such as poly(lactic-co-glycolic acid) (PLGA), silicone and collagen for 
application as biomaterials. Importantly silk proteins break down into amino acids that can be 
absorbed by the body (3). The rate at which silk proteins break down can be controlled by 
altering the crystallinity of the structure by changing the temperature, pH or solvents used 
when producing drug delivery systems (3). The increased degree of crystallinity yields a 
slower release of the encapsulated drug, resulting in longer effect and less frequent dosing of 
the drug  (1, 4). 
Silk fibroin, the major protein in silk, has been widely established as a platform for controlled 
drug delivery of various drugs via formulations of microparticle, spheres, film, coating, and 
hydrogel (1, 4). For example, silk fibroin coating on liposomes loaded with emodin (a model 
drug) enhanced the delivery of emodin to breast cancer cells and the overall efficacy of the 
drug (5). Silk scaffolds have been used for tissue engineering and furthermore have been 
developed for three-dimensional (3D) disease models, leading to advances in cancer models 
and therefore, cancer therapy research (1, 6). It is expected that even more applications of silk 
as biomaterial will be discovered through the current research focus. 
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2. Silk as a biomaterial 
2.1. Sources and types of silk used as biomaterials 
Silk produced by silkworms and spiders are the main natural sources of silk researched for 
biomaterial applications (7). Currently, more silk-based biomaterials are being sourced from 
silkworms due to easy domestication as well as widely established processing and production 
(7). Nearly 1000 metric tons of silk per year are produced in the global textile industry and 
the yield of fibre from a single silkworm cocoon is 600 – 1500 m (8). On the other hand, the 
lack of large-scale production systems as well as the cannibalistic nature of spiders and the 
heterogeneous nature of spider silk are limitations of using spider silk as biomaterials (8-10). 
With advancement of research in recombinant proteins, spider silk is increasingly 
investigated in its engineered and recombinant forms for biomaterial applications such as 
controlled delivery of protein drugs (10).  
Hofer et. al. have pointed out that silk proteins obtained naturally from silkworms may vary 
in quality due to the inherent differences within the various species of silkworm, each 
individual silkworm and the various degumming processes that each silkworm species 
possesses (10). They identified that these qualities amounted to difficulties in ensuring 
quality control of delivery systems that are formulated from natural sources of silk, and 
therefore introduced recombinant spider silk as a promising biomaterial for novel drug 
delivery systems (10, 11).  
Recombinant spider silk protein, known as ―spidroin‖, can be potentially used as a form of 
drug delivery vehicle, yet very few controlled studies of the properties of spidroin exist (9). 
The superiority of specific recombinant spidroin protein over fibroin in the behaviours of the 
scaffolds for bone tissue regeneration was demonstrated recently by Moisenovich et. al., and 
therefore suggested promising applications for recombinant spider silk proteins (12). 
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Silkworms belong to the families Bombycidae or Saturniidae and produce silk which are 
classified as ―mulberry‖ or ―non-mulberry‖ as illustrated in Figure 1 (13). Mulberry silk, 
produced by the commonly domesticated Bombyx mori (B.mori), is the most widely 
researched type due to its finest quality of raw silk and the highest fiber production (13, 14). 
Antheraea mylitta (A.mylitta) is a wild silkworm, from one of three types of species 
belonging to Saturniidae family and it produces non-mulberry silk which is increasingly 
studied for potential use as a biomaterial due to its tensile strength and larger cocoon size 
compared to B.mori (13). Wild silkworm cocoons have higher tensile strength compared to 
domesticated silkworm cocoons as the need to protect themselves from environmental 
hazards has necessitated such natural quality (15). In the area of cardiac tissue engineering in 
particular where the heart is constantly contracting, fibroin from A.mylitta is preferred as it 
possesses more favourable mechanical properties including elasticity and tensile strength (16). 
For this project, silk fibroins from both species of silkworm were used as they were the most 
readily available and the most widely researched species for biomedical uses of silk. 
 
 
 
 
 
 
Figure 1. Types of silk, species and families of silkworms for biomaterial use  
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2.2. Composition of silk from silkworms 
Both mulberry and non-mulberry silk consist of two biodegradable proteins, fibroin and 
sericin. Tao et. al. states that – silk proteins represent a unique family of biopolymers due to 
their structural and biological properties‖(17). Fibroin is the major, structural protein proven 
to be biocompatible through many biomedical applications (18). This protein consists of a 
heavy chain (395 kDa) and a light chain (25 kDa) linked by a single disulfide bond and is 
formed with repeats of amino acid sequences consisting of glycine, alanine, and serine (19).  
Sericin constitutes about 20-30% of the total cocoon weight, and is less studied compared to 
fibroin despite its potential advantages (14). The comparison of fibroin and sericin from the 
most extensively studied B.mori silkworm are summarised in Table 1 below. Noting the 
extensive literature and study around fibroin, attempts to discover the potential of currently 
under-utilised sericin for novel biomaterial uses, especially with recent evidence indicating 
that sericin has natural antibacterial characteristics, are outlined in section 2 of Research 
Proposal (20). 
 
2.3. Applications of silk fibroin 
The scope of applications of silk as biomaterials has broadly expanded in the last few decades. 
Examples of their application include implants, coatings to control drug release, tissue 
engineering as well as vascular and nerve regeneration (1, 8, 21). Silk fibroin biomaterials 
have also been used for plastic and reconstructive surgery, in which slow biodegradation and 
good mechanical properties are critical (8). 
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Table 1. Comparison of silk proteins from the cocoons of mulberry silkworm B.mori  
Protein Fibroin Sericin 
Composition Amino acids in a heavy chain 
and a light chain in a 1:1 ratio 
linked by disulfide bonds (22) 
Polypeptide polymer consisting of 
18 amino acids (23) 
Type of protein Structural protein Glue-like protein 
Proportion of cocoon 70% 20-30% 
Structural 
properties 
Hydrophobic;  
β-sheets and α-helices 
Hydrophillic; remains in a partially 
unfolded state, with high 
proportion of random coil structure 
(23) 
Molecular weight 26-370 kDa 24-250 kDa 
Major properties Biocompatible, biodegradable, 
crystallinity, mechanical 
properties, opportunity for 
chemical functionalization 
(24) 
Antibacterial, UV-absorbing, high 
moisture absorbancy, antioxidant, 
antitumor, wound-healing (25) 
Novel applications Drug delivery, tissue 
engineering, implant coating, 
imaging and diagnostics (24) 
Food, cosmetics, drug delivery, 
medical and pharmaceutical 
industries 
Advantages for use 
in drug delivery 
Aqueous processing, 
controllable biodegradation 
Capable of carrying both 
hydrophilic and hydrophobic drugs 
(13) 
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Silk fibroin as a platform for controlled drug delivery has been widely established and is 
currently under further investigation for delivery of growth factors for tissue repair, as well as 
for applications to cancer therapy and treatment of epilepsy (1, 4). It was noted by Kundu et. 
al. that a more extensive understanding of the long term biocompatibility and 
biodegradability would lead to an ability to tailor silk-based biomaterials to meet tissue 
specific requirements (8).  
The suitability of silk fibroin in drug delivery is attributed to its assembly and the ability to 
modify it. The structure of silk fibroin consists of alternating hydrophilic and hydrophobic 
blocks (Figure 2) (22). Functional groups including amines, alcohols, phenols, carboxyl 
groups, and thiols can be chemically modified or functionalized to improve interaction with 
other small molecules (1).  
 
 
 
 
 
 
 
 
 
Figure 2. The physical and chemical structure of fibroin (22) 
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Functionalization is also beneficial as it promotes cell adhesion and spreading during delivery 
of the incorporated drug (1). Moreover, the structure of fibroin allows for hydrogen bonding 
or covalent attachment of proteins and compounds. It also offers a highly stabilising 
environment for a variety of incorporated molecules including proteins and bioactive 
molecules (18).  
Silk fibroin functionalised by chemical modification of the potentially reactive side groups, 
has shown possible application in microfluidics, optics and photonics or electronic 
devices/biosensors (17). Recently Zhang et. al. demonstrated that functionalised silk fibroin 
films can provide stabilisation of vaccines and antibiotics, in order to potentially eliminate the 
need for refrigeration while transporting vaccines to developing countries (21).  
Despite very broad use of silk in biomedical applications (and beyond), its potential as a drug 
delivery carriers for the drug delivery to the lungs has not been investigated and silk-based 
delivery systems are yet to be developed into an inhalable form. Therefore, this project will 
strive to develop novel, biologically-inspired silk-based inhalable drug delivery systems that 
target the lungs. It is desired that such drug delivery systems will work synergistically with 
the already established treatment regimens for lung cancer. 
 
2.4. Potential antibactieral action of silk proteins 
Silk cocoons are designed to protect silkworms from their surroundings including 
environmental stresses and physical attacks (15). Their functions include defence from 
predators, thermal regulation and the antibacterial function for the survival of the silkworm 
contained inside the cocoon (15). Researchers have been investigating silk materials in the 
light of their above-mentioned natural functions.  
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The antibacterial action exhibited naturally by silk proteins was investigated by Senakoon et. 
al. in 2009 and the zone of inhibition and minimum inhibitory concentration of sericin in 
Escherichia coli (E.coli) and Staphylococcus aureus (S.aureus) were documented (20). The 
results showed significantly reduced growths of both E.coli and S.aureus in the presence of 
sericin and thus it was concluded that sericin has antibacterial attributes against both Gram 
positive and Gram negative bacteria (20). Further studies however were required in this area 
because the above result was derived from experiments using only one particular species of 
silkworm; eri silkworm (Samia ricini). This will be investigated in this project for potential 
application of silk-based carriers for delivery of antibiotics. 
 
3. Rationale for uses of silk proteins as drug carriers 
3.1. Biocompatibility 
Biocompatibilities of both fibroin and sericin are now well established (19, 26). Silk fibroin 
based formulations are valuable not only due to their non-toxic and non-antigenic nature, but 
also their stability during storage as well as in vivo (19). Wang et. al. has investigated the 
effects of silk fibroin coatings on PLGA and alginate microspheres for protein delivery. Silk 
coatings made beneficial changes to the surface properties of the PLGA and alginate 
microspheres and improved the biocompatibility of the particles when compared with the 
same tests undertaken with uncoated microspheres used as control (27). Additionally, their 
investigation observed that silk fibroin coatings prevented PLGA microspheres from 
aggregation and decomposition and therefore maintained their spherical shapes for two weeks 
as well as providing stabilisation from degradation (27). Furthermore, the ability to control 
coating thickness and crystalline content, together with the observed controlled protein drug 
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release, leads to silk fibroin acting as an effective diffusion barrier (27). The findings from 
this study can be used to broaden the scope of applications of silk fibroin. 
A recent study by Qu et. al. demonstrated the behaviour of cells on the surface of silk fibroin 
microspheres and tight cell attachment indicated that silk fibroin is biocompatible (28). Qu et. 
al. also investigated the effect of cell growth depending on the size of the microspheres, and 
found that the smaller the silk fibroin particles, higher the cell proliferation due to larger 
specific surface area and higher number of pores compared to larger particles. Cell 
proliferation rate is accelerated with larger surface area provided by smaller sized spheres 
(28). 
A cell viability assay conducted by Kundu et. al. demonstrated that the number of viable cells 
growing on silk fibroin microspheres rapidly increased on days 3 and 5 (19). By day 7, there 
was a large difference between silk fibroin microspheres with control group, due to the silk 
fibroin microspheres providing more space for cell growth and proliferation (19). 
 
3.2. Biodegradability 
The degradation behaviour of silk is important to understand when investigating it as 
therapeutic drug carriers. The degradation rate of silk biomaterials should be optimised to 
match the functional needs, for example, in the application of tissue engineering, the 
degradation rate of the scaffold should match the rate of tissue growth (3). For the application 
in tissue engineering, understanding of degradation is vital and it leads to successful control 
of cellular metabolism and differentiation (29). The process of biodegradation is one of the 
critical factors for success of a biomaterial in clinical applications (29). The degradation 
behaviour of sericin is not as well established and remains to be investigated in detail, 
however there are numerous studies evaluating the degradation of fibroin. 
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Being a natural polymer, fibroin degrades into amino acids glycine, alanine and serine, which 
are easily absorbed in vivo. Cao and Wang conducted in vitro studies to show that these 
amino acids resulting from the degradation of fibroin were taken up by the cells for further 
metabolism (3). This highlights the previously mentioned superiority of silk fibroin to one of 
the most commonly studied biodegradable polymers, PLGA, which degrades via hydrolysis 
into acidic products resulting in a low pH environment which in turn imposes detrimental 
effects on the incorporated drug (30). 
Silk fibroin sheets were shown to degrade by 70% in 15 days when exposed to protease XIV 
(3). Fibroin is water soluble in its random coil and helical conformation, whereas it is water 
insoluble in its crystalline β-sheet conformation that may be induced by the use of organic 
solvents, increased temperature and altered pH level (31). In contrast to earlier studies where 
the rate of degradation was mostly associated with the molecular weight, structure and the 
level of crystallinity, Rajkhowa et. al. demonstrated that reduced crystallinity as well as high 
surface area and porous morphology increases the degradation of silk particles (3, 29). 
In the case of porous silk particles, the mechanism of degradation is believed to be through 
hydrolysis by protease XIV contributing to pore surfaces fracturing into finer particles (29). 
This mechanism explains the increase in degradation rate, compared to the previously 
understood degradation by surface erosion mechanism alone. The mass loss of 60%, 
compared to 23% in a 12-day period, together with the observed reduction of particle size 
towards the end of the degradation tests, supported their conclusion (29). 
Determining the exact biodegradation behaviour of silk is challenging due to other 
influencing factors such as a protease inhibitor in the silk gland embedded in the cocoons of 
B.mori, produced by silkworm itself, as well as gamma radiation causing reduction in the 
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tensile strength of fibroin fibers and thus increasing the rate of biodegradation of silk fibroin 
(3). 
 
3.3. Superiority of silk fibroin compared to other polymer biomaterials for drug 
delivery 
Although PLGA is the most extensively studied synthetic polymer for use as a drug carrier 
system, suitability for delivery of protein drugs is challenging due to the requirement of 
organic solvents for processing and reduction of pH caused by polymer degradation (32). In 
contrast, silk fibroin can be processed in an aqueous environment and is capable of being 
degraded into amino acids that are well absorbed by the body (32).  
In the application for drug delivery it is significant that silk, unlike other polymer 
biomaterials, can be processed in aqueous systems in mild conditions of temperature, 
pressure and neutral pH, without the need of harsh manufacturing conditions that may 
potentially damage the incorporated drug (8, 24, 30). The process of extraction of fibroin and 
sericin from the cocoons of B.mori silkworms is shown in Figure 3. Silk fibroin can be 
prepared into various morphologies such as films, hydrogels, microspheres, sponges and 
nanofibres to suit different applications (18, 32). Chitosan and gelatin particles as drug 
carriers for protein delivery were also faced with limitations due to organic solvents being 
required as crosslinking agents to prevent the burst release of the encapsulated drug (32).  
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Figure 3. Extraction of fibroin and sericin from the cocoons of B.mori silkworms (24, 33).  
 
3.4. Recent applications in drug delivery for the treatment of cancer 
By using carriers, specific sites of cancer can be targeted and also the slow release 
formulations allow lowering of the required dose, therefore the common toxicity and side 
effects of anticancer drugs can be also reduced. 
Silk films loaded with doxorubicin were evaluated for in vivo performance in primary breast 
cancer in mice and they provided reduced tumour growth and reduced metastatic spread (34). 
Silk fibroin and sericin can be prepared into nanoparticles or microparticles. The advantages 
of using nanoparticles as carriers of drugs include sustained drug release, reduced drug 
toxicity, as well as lesser frequency of dose administration (35). This is of great benefit to 
cancer treatment over the traditional intravenous chemotherapy, as the drug-loaded 
nanoparticles reach and stay in the target tissue and release the drug gradually to act on the 
growing cancer cell (31). Similarly, this thesis aims to provide an insight into improving local 
delivery of anticancer drug to the lungs via silk-based microparticles for better outcomes, 
including longer action of the delivered drug whilst having less systemic side effects. 
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3.5. Drug encapsulation and release 
Loading and release of various drugs carried by silk fibroin particles have been studied in 
vitro and have demonstrated successful cellular acceptance of both the particles and the 
encapsulated drugs (36). High encapsulation efficiency was seen in drugs with high 
molecular weight, hydrophobic affinities and release rates were directly related to surface 
charge (36). A recent study of the in vitro release behaviour of encapsulated drugs found that 
the silk particles that are positively charged released the drug in a more prolonged fashion 
(37).  
Crosslinking increases the surface hydrophobicity and thus leads to slow-release mechanisms; 
however it has been shown that the silk particle uptake and release of water-soluble drugs is  
mostly dependent on silk particle formation rather than crosslinking (38). 
The rates of drug release are dependent on diffusion of drug through the silk, degradation of 
the silk fibroin carrier, or both (4). By manipulating the secondary structure of silk fibroin 
particles, the physicochemical properties may be manipulated in order to achieve controlled 
delivery to desired sites (7). Diffusion can be controlled by engineering morphology of silk 
fibroin carrier particles including their geometry, number and thickness of coating and 
porosity (24). The degradation of silk fibroin in vivo, and thus the release of its encapsulated 
drug can be controlled by using organic solvents, different silk concentrations, porosities, or 
altering crystallinity via regulation of β-sheet content during processing (22). 
Silk fibroin has organised crystalline β-sheet conformations that stabilise its structure via 
physical crosslinks (21). Furthermore, the control of β-sheet content by altering the 
conditions during processing allows alteration in the level of crystallinity and thus allowing 
for the control of the release properties of the incorporated drug(s) (22). This structure 
explains the outstanding mechanical properties of silk fibroin to withstand load and 
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compression which are superior to other studied polymer biomaterials such as silicone, 
PLGA and collagen (1). 
Recently Kundu reported an in vitro drug release study on tumour cells using silk fibroin-
albumin nanoparticles as carriers to deliver methotrexate (39). The results of their study 
proved that methotrexate without any carrier was released almost completely within the first 
two days, and when silk fibroin was used, the release rate was significantly slower (Figure 4). 
The albumin blended together with silk into nanocarriers had resulted in the methotrexate  
being released gradually with very little burst release.  
 
 
 
 
 
 
 
 
 
Figure 4. Drug release profile of methotrexate (MTX) released from silk fibroin (SF), silk 
fibroin-albumin (in ratios of 1:1, 2:1, 1:2) or albumin (Alb) nanoparticles into phosphate 
buffer solution at 37˚C (39). The results were evaluated by mean ± standard deviation for n = 
3. This data was reproduced with permission from the authors of the article. 
 
26 
 
In this study, the nanoparticles were prepared in three different ratios of silk fibroin and 
albumin blends 2:1, 1:1 and 1:2 (v/v). Blending the two components together led to strong 
electrostatic interactions between the carboxyl groups of hydrophobic silk fibroin and the 
amino groups of hydrophilic albumin, and therefore successfully prevented leakage and 
improved encapsulation, drug retention and release rate (39). The initial burst release was 
avoided which therefore indicated the potential lowering of the incidence of side effects and 
toxicity of methotrexate (39). This study demonstrated that silk formulations can be modified 
into combinations with other proteins (e.g. albumin) and promoted silk nanoparticles as 
superior carriers of drug with controllable drug release characteristics.  
The release mechanisms of a drug from porous silk fibroin microspheres were found to be 
outwards drug diffusion due to the swelling of the silk fibroin matrix, as well as the 
degradation and erosion of the silk fibroin matrix (40). The in vitro release behaviours of 
methylene blue (a model drug) from various silk fibroin microspheres formulated using 
water-in-oil emulsification-diffusion method were investigated by Imsombut et. al. for 
developing controlled drug delivery applications (40). The higher the ratio of methylene blue 
to silk fibroin, the higher was the burst release rate, since the drug concentration gradient was 
a major factor in the first 12 hours of drug release via swelling of the silk fibroin matrix (40). 
Therefore the optimisations of concentration of drug in the formulation, as well as controlling 
the degradation rate of silk fibroin, are critical for successful applications of silk fibroin as 
drug delivery systems. 
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4. Rationale for development of inhalation treatment for lung cancer 
4.1. Epidemiology and trend in research funding 
Scientific research related to the treatment of lung cancer has failed to significantly improve 
prognosis in the last several decades (41). The 5-year survival rate has not improved over the 
last 30 years, and lung cancer still causes more deaths than colon, breast and prostate cancers 
combined (42, 43). Similar data was presented graphically by the American Cancer Society 
which showed a significantly higher rate of cancer deaths caused by lung and bronchus 
cancer compared to other sites of cancer (Figure 5) (44). The highest rate of death caused by 
lung and bronchus cancer was reached in the early 1990s for males and late 1990s for females. 
Despite the rate decreasing, it still remains higher than other sites of cancer.  
Each year, between 1.3 and 1.5 million people are newly diagnosed with lung cancer 
worldwide and the number of new diagnoses is expected to continue increasing with the 
epidemic of tobacco use (43). Data from the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) study from 2003 to 2009 shows that the percentage 
of survival from lung and bronchus cancer in the United States is 16.6% (45). The 5-year 
relative survival rate, although diagnosed during the localised stage, is as low as 53.3% (45).   
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Figure 5. Cancer death rates by site of cancer, age-adjusted per 100,000 (a) male population 
or (b) female population in the US from 1930 to 2008 (44). Reproduced with permission from 
the American Cancer Society, Cancer Facts & Figures 2014 
 
A review of research funding for ―hard-to-treat‖ cancers by the UK National Cancer 
Research Institute (NCRI) in 2002 found that research funding spent for lung cancer did not 
reflect the fact that it was one of the most common and hard-to-treat cancers (46). The 
percentage of research funding spent by the NCRI for lung cancer was found to be lower than 
other cancers despite lung cancer having the highest percentage of total cancer deaths (Figure 
6) (47). Since then, there has been an increase in the awareness of the need for lung cancer 
research and the site-specific cancer research funding for lung cancer has increased from £3.5 
million in 2002 to over £11 million in 2010 (Figure 7) (46). 
(a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 6. The percentage of total cancer deaths in the UK by tumour site (shown in blue) and 
the site-specific cancer research funding spent by NCRI (shown in red) (47). Reproduced 
with permission from the Pancreatic Cancer Society, UK 
 
 
Figure 7. Percentage of site-specific research funding for cancers in 2002 and 2010 (46).      
* shows the significant increase in research funding for lung cancer. Reproduced with 
permission from National Cancer Research Institute, UK 
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4.2. Advantages and challenges of pulmonary delivery 
Targeted delivery of drugs to the lungs for the treatment of chronic lung infections, lung 
cancers, tuberculosis and other respiratory conditions has been emerging as an innovative 
area of research in the last decade (48, 49). Potential advantages of targeted delivery include 
the reduction of dosage and side effects of the drug compared to systemic drug delivery (49). 
While the majority of commercially available inhalation products are for local treatment of 
lung diseases, a number of inhalation products designed to treat systemic diseases are 
undergoing clinical development (50). The lung is an attractive target for drug delivery due to 
the avoidance of first-pass metabolism, the large surface area and the rapid onset of action 
leading to enhanced absorption of drugs (49, 51, 52). Also, the limited proteolytic activities in 
the lungs reduce the metabolism and clearance rate which allows for longer action of the drug 
(49). 
Further research is needed to understand the physicochemical properties of particles delivered 
to the lungs (49). Developments in drug carriers designed to enhance aerosolisation 
efficiency and lung deposition of the drug found major challenges in formulation (53). These 
challenges include fabricating particles with adequate aerodynamic properties, drug release, 
appropriate biodegradation and avoidance of particle uptake by macrophages that prevent 
drugs from reaching the site of action (53). 
Recently, polymeric particles in the application of drug delivery to the lungs has been widely 
researched due to their biocompatibility, surface modification capability and controlled-
release properties (52). More specifically, biodegradable polymers are recognised as 
promising excipients for sustained release formulations (54). There have been developments 
to the formulation of polymeric particles from biodegradable polymers, such as polylactic 
acid carrying cisplatin for targeted drug delivery (55). These polymeric particles 
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demonstrated the advantages of longer circulation half-lives and drug accumulation at the 
tumour sites (55, 56). However, further long term biodegradability and toxicity studies are 
required in order to avoid harmful accumulation of polymeric particles in the lungs (52).  
The importance of long term studies was seen in the case of novel drug delivery systems for 
doxorubicin for the potential treatment of lung cancer. In 2008, polysorbate-80-coated 
nanoparticles loaded with doxorubicin were formulated and the in vitro studies demonstrated 
more effective cytotoxicity compared to free doxorubicin (48). The results showed that the 
doxorubicin-loaded nanoparticles were more readily internalised via endocytosis compared to 
free doxorubicin entering cells by passive diffusion mechanisms (48). This study was 
concluded with a promising outcome for the development of inhalable nanoparticles loaded 
with anticancer drugs. A study by Al-Hallak et. al. in 2010, found that the polysorbate-80-
coating caused pulmonary toxicity and decreased tolerance in both in vitro and in vivo studies 
(48, 57). In 2011, Roa et. al. developed carrier particles consisting of sodium carbonate and 
lactose monohydrate in two different forms – effervescent and non-effervescent – to deliver 
doxorubicin in vivo to mouse models (58). The results showed that inhalable effervescent 
nanoparticle powder was an effective delivery vehicle with a significantly longer survival 
time compared to the intravenous administration of the same drug dose (58). This case of 
doxorubicin delivery for lung cancer highlighted the need for long term studies in developing 
novel drug delivery systems. 
 
4.3. Anticancer drug delivered via inhalation 
Novel routes for the administration of cancer therapies have been investigated for decades 
(59). Among the novel routes, pulmonary drug delivery for treatment for lung cancer has 
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been widely researched in the last two decades due to many obvious advantages including 
reduction of dosage required and therefore reduced systemic side effects (59).  
Cisplatin is a platinum-based first-line chemotherapy drug for lung cancer currently delivered 
intravenously (56). The conventional cisplatin formulation delivered intravenously is widely 
distributed into body fluids and tissues and rapidly bind to tissue and plasma proteins, leading 
to low bioavailability to the target organ (60). The majority of the drug fails to reach the 
target site in the lungs and instead, highest concentrations are found in the kidneys and is 
excreted from the body predominantly via renal excretion (60). Thus there are common 
systemic side effects such as nephrotoxicity, ototoxicity, mucositis and mylosuppression 
often leading to life-threatening septicaemia (60, 61). Furthermore, the cytotoxic effect of 
cisplatin in currently marketed formulations is short lasting and requires frequent dosing to 
maintain the concentration of the drug within the therapeutic window (60). This increases the 
costs to healthcare because a health care professional is required for the administration of 
every intravenous dose (60).  
Selting et. al. stated that inhaled cisplatin is a promising method of treatment for both 
primary and secondary lung tumours with minimal serum concentration of cisplatin detected 
compared to intravenous cisplatin (62). This was demonstrated in the in vitro release study of 
cisplatin-loaded albumin nanoparticles by Das et. al. and from a study investigating the  
extended cytotoxic activity of core-surface-cross-linked nanoparticles loaded with cisplatin 
by Xu et. al. (60, 63). When nano- or micro-carrier molecules are used to deliver cisplatin, 
the ability to deliver drugs preferentially to cancer tissues allowed for enhanced therapeutic 
efficacy and reduced side effects (63). Additionally, cisplatin is released over a longer period 
of time, leading to enhanced cytotoxic effects (60, 63).  
In 2007, cisplatin encapsulated in aerosolised sustained release lipid vesicles were developed 
and a phase I clinical study was conducted to investigate the safety and pharmacokinetics in 
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humans (64). This study recruited 17 patients with primary cancer of the lung or metastatic 
cancer to the lungs with a life expectancy of at least 12 weeks who had no other standard 
treatment available for them due to unresponsiveness (64). Around 40 to 50% of the 
encapsulated cisplatin was released immediately and the remaining 50 to 60% of total 
cisplatin was found to be delivered in a sustained release manner. The study concluded that 
this treatment was feasible and safe as the adverse effects experienced by the patients were 
the general adverse effects of chemotherapy such as nausea and vomiting. Also, most other 
adverse effects experienced by the patients – dyspnoea, productive and irritative cough, and 
hoarseness – were not specific to the direct effects of cisplatin delivered by inhalation, but 
instead were due to an inhaled compound to the respiratory tract (64).  
 
5. Summary 
Silk proteins are widely established as drug delivery platforms; however, to our knowledge 
there are no inhalable formulations of silk proteins. A drug carrier is required in order to 
deliver drugs to the lungs in order to optimise delivery to the site of action and silk proteins 
are good candidates due to the properties described above.  
The silk-based carriers were designed for potential application in delivery of various drugs, 
however with the given time frame, two types of drugs were investigated in this project – 
antibiotic and anticancer drugs.  
Targeted delivery of antibiotics via inhalation using silk carriers would be beneficial for 
many patients with regular or frequent uses of oral or intravenous antibiotics for infections in 
the respiratory tract, especially with some evidence that sericin naturally possesses 
antibacterial actions (20). 
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It is clear that there is a need of better treatment regimens for lung cancer. Targeted delivery 
of cisplatin to the lungs may improve the side effect profile of currently injected cisplatin. 
When silk fibroin is cross-linked in order to deliver cisplatin at a modified release, the 
cytotoxicity of cisplatin may be also improved.  
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II. Research Proposal 
1. Significance and aims of the project 
This project is focused on the development of new silk-based particles for localised delivery 
of anticancer drugs to the lungs. Apart from the instance where sericin was formulated into 
inhalable particles via spray drying by Genc et. al, silk has not been developed into drug 
carriers for pulmonary delivery (20, 51). This project aims to optimise the formulation of 
inhalable silk-based particles to act as carriers for cisplatin, an anticancer drug, for potential 
treatment of lung cancer through pulmonary delivery. Also, cytocompatibility studies were 
conducted to investigate the effects of silk on lung cells, and to observe differences between 
the cytotoxic effects of cisplatin when formulated with various silk-based particles. 
Cisplatin was the chosen anticancer drug to be delivered using the silk-based carrier particles 
for two main reasons:  
 The systemic adverse effects such as nephrotoxicity, ototoxicity, mucositis and 
mylosuppression, can be minimised through targeted local delivery (60).  
 Currently marketed formulations of cisplatin are short lasting and require frequent 
dosing, therefore the controlled release formulations of cisplatin are considered to be 
valuable (60). 
Currently, there is no commercially available product for the controlled release medications 
through inhalation. Often inhalation medications need to be administered two to four times 
daily leading to poor patient compliance (54).  
For the case of silk fibroin, a crosslinking agent was required to achieve controlled release 
properties. Genipin was the ultimate choice for the purpose of this project as the 
cytocompatibility studies of genipin conducted previously confirmed the safety of genipin to 
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use as biomaterials (65, 66). Therefore, no additional experiments were required to prove the 
cytocompatibility of genipin for this project. Genipin is described as a non-toxic crosslinking 
agent for silk fibroin in biomedical applications that could ―maintain the biocompatibility, 
bioactivity as well as improving the water resistance and mechanical properties of silk fibroin 
materials‖ (65). 
Fabrication of the silk-based particles was conducted using two methods – spray drying and 
spray-freeze-drying. Spray drying is a relatively simple, one-step process to convert silk-
based aqueous solutions into dried particles with narrow particle size distributions (54). 
However, a shortcoming of the spray drying method is that varying yields are produced. 
Spray-freeze-drying is an efficient method with high yields of up to almost 100%. Despite the 
requirements of longer time, more caution with handling cryogenic fluids and higher costs, 
spray-freeze-drying produced particles with favourable characterisation and aerosolisation 
performance (54).  
Spray-freeze-drying protein formulations require the use of a lyoprotectant – a sugar or sugar 
alcohol – to protect the protein structure in the low temperatures during the drying process. 
However, the inclusion of sugar in the formulations has additional benefits as it improves 
stability and acts as a matrix-former to prevent agglomeration upon drying (67). Sucrose, 
trehalose and mannitol, all of which are sugars, were used as lyoprotectants in the 
formulation of silk-based particles. Mannitol is an approved excipient for dry powder inhaler 
formulations while trehalose is listed as one of the promising alternatives (54). The 
differences between the formulations arising from the choice of lyoprotectant were also 
identified in this project. 
 
37 
 
2. Specific aims 
 To demonstrate that the novel silk-based formulations are inhalable and could be 
developed into controlled release delivery systems. 
 To show that silk proteins naturally exhibit antimicrobial actions and that the silk 
formulations can synergistically enhance the efficacy of antibiotics. 
 To demonstrate the cytocompatibility of the silk-based formulations.  
 To compare the cytotoxicity of the normal or cross-linked silk-based cisplatin 
formulations. 
3. Research plan 
The following is a flow chart for the process of the formulation and optimisation of silk-
based particles for lung delivery. At each step of the formulation, the particles were 
characterised to develop an optimised formulation for silk-based cisplatin particles.  
 
 
Figure 8. The process for formulation of silk-based particles for optimised formulation of 
silk-based cisplatin particles for pulmonary delivery 
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III. Materials and methods  
 
1. Formulation of silk-based particles 
1.1. Source of materials 
Silk proteins (fibroin and sericin) extracted from both A.mylitta (AM) and B.mori (BM) 
species of silkworm were kindly supplied by Professor Kundu, the Department of 
Biotechnology, Indian Institute of Technology Kharagpur, prepared in scaffolds (fibroin) or 
powder (sericin) form. All other chemicals were purchased from Sigma-Aldrich (Castle Hill, 
Australia). 
 
1.2. Silk protein solution preparation 
The silk scaffolds or powder were weighed and cut into appropriate sizes to be dissolved in 
deionised water at concentrations ranging from 0.1% to 2% (w/v) with heating at 45C and 
sonication for 10 minutes. Undissolved silk fibroin parts were removed by filtering through 
0.22 µm syringe filters (Millipore, Millex
®
 GP Filter Unit, Millipore Express PES Membrane, 
Darmstadt, Germany). For spray-freeze-drying silk solutions, a lyoprotectant (sucrose, 
trehalose or mannitol) was incorporated at concentrations of 0.5% or 1% (w/v). All solutions 
were prepared fresh on the day of experiment and were stored at 2 – 8 C before use.  
 
1.3. Incorporation of drug to silk solutions 
The antibiotics used were ciprofloxacin and gentamicin, incorporated to silk solutions 
prepared for spray drying, at concentrations of 0.07% or 1% (w/v). Cisplatin was the chosen 
anticancer drug, incorporated to silk solutions prepared for spray-freeze-drying, at 
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concentrations of 0.05% or 0.1% (w/v). Drugs were weighed and dissolved in deionised 
water prior to mixing with the silk solutions.  
 
1.4. Crosslinking of silk fibroin for controlled release of drug 
Prior to adding drug to the silk solutions, genipin was added to the silk solutions at a 
concentration of 0.05% (w/v) in order to produce formulations of silk cross-linked with 
genipin. The solution was mixed using a magnetic stirrer for 15 hours at room temperature. 
 
1.5. Fabrication of particles from spray-drying  
Silk solutions with or without drug were prepared for spray drying using a lab scale spray-
dryer (Büchi Mini Spray-Dryer B-290, Büchi Labortechnik, Flawil, Switzerland). The spray 
dryer was used in an open loop, with Büchi Dehumidifier B-296 in blowing mode. The 
operation condition used were as follows: liquid feed rate at 1.7, 3.5, 4.2 and 4.8 ml/min, 
aspiration at 100%, airflow with gas supply pressure 50-60 mbar, and inlet and outlet 
temperatures at 120 ºC and 61-87 ºC, respectively.  
 
1.6. Fabrication of particles from spray-freeze-drying  
The solution prepared for spray-freeze-drying was placed into a syringe fitted onto a PHD 
2000 syringe pump (Harvard Apparatus, Holliston, MA, USA), used to feed solution at a rate 
of 0.5 ml/min through an ultrasonic nozzle (Sonozap 130K50ST), powered by an ultrasonic 
generator (Sonaer Inc, New York, USA). Particles were collected in a beaker containing 
liquid nitrogen, in an insulated tub containing liquid nitrogen surrounding the beaker to keep 
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stable temperature. Samples were transferred into the freeze dryer (Christ Alpha 1-4, B.Braun 
Biotech International, Melsungen, Germany) for drying under vacuum. The temperature was 
set to -20ºC, for 24 hours for primary drying, followed by secondary drying at increasing 
temperatures of 10ºC per hour until final temperature of 20ºC was reached. The vacuum was 
set to 0.1 mbar, however actual vacuum measured was between 0.07 - 0.12 mbar. 
 
Table 2. A list of silk-based particles formulated for the purpose of this project 
Method of production Formulation Concentration ratio 
Spray dried silk alone 
BM fibroin only 
N/A 
 
AM fibroin only 
BM sericin 
AM sericin 
Spray dried silk + antibiotics 
BM fibroin + ciprofloxacin 10:1 
AM fibroin + ciprofloxacin 5:1 
AM fibroin + gentamicin 5:1 
Spray-freeze-dried silk alone 
BM fibroin + sucrose 2:1 
BM fibroin + trehalose 1:1, 2:1, 1:2 
BM fibroin + mannitol 1:1 
AM fibroin + trehalose 1:1 
Spray-freeze-dried silk + 
cisplatin 
BM fibroin + trehalose + 
cisplatin 
1:1:1, 5:5:1, 10:5:1 
AM fibroin + trehalose + 
cisplatin 
5:5:1 
BM fibroin + mannitol + 
cisplatin 
5:10:1, 10:20:1, 
10:8:1 
Spray-freeze-dried cross-linked 
silk + cisplatin 
BM fibroin + mannitol + 
cisplatin + genipin 
10:20:1:1 
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2. Characterisation of silk-based particles for pulmonary delivery 
2.1. Assessment of particle size and morphology 
2.1.1. Particle size distribution by dynamic light scattering  
Geometric particle size and the size distribution of the particles were measured by laser 
diffraction using Mastersizer (Malvern Instruments, Worcestershire, UK). Dry dispersion 
with refractive index of 1.0 was used. Triplicate samples were analysed for reliability. Mass 
median diameter (D(0.5)), which represents the diameter at which 50% of the particles had by 
mass are larger and 50% are smaller, was identified, and this was considered as the average 
particle diameter by mass. 
 
2.1.2. Particle size and morphology 
Scanning electron microscopy (SEM) was used to observe the morphology and size of the 
particles after producing each batch of particles. Samples were dispersed onto carbon tape, 
mounted on SEM stubs, and sputter coated with approximately 20 nm thick gold using a 
K550X sputter coater (Quorum Emitech, Kent, UK). Images were obtained using Hitachi S-
4500 field emission scanning electron microscope (Hitachinaka-shi, Ibaragi, Japan). The 
approximate particle sizes observed in the SEM micrographs were used to alter the 
parameters for the formulation of fibroin particles. 
 
2.1.3.  Three-dimensional analysis of surface topography 
Atomic force microscopy (AFM) was used for observing particle size and imaging 3D 
surface topography. The particles were dispersed onto Tempfix
®
 (Plano GMBH, Wetzlar, 
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Germany) prepared on a glass slide. MFP-3D-BIO
TM
 AFM (Asylum Research, Santa Barbara, 
USA) was used in AC mode and images were produced in 256 x 512 sample points at a scan 
rate of 0.30 – 0.40 Hz and scan size 600 nm – 1.5 µm. The images were processed into colour, 
3D images and were analysed using the Igor Pro software program (Version 6.22A, Asylum 
Research, Santa Barbara, USA).  
 
2.2. Determination of amorphous or crystalline structures 
To determine whether the particles are amorphous or crystalline, an X-ray diffractometer 
(XRD-6000, Shimadzu Scientific Instruments, Tokyo, Japan) was used to measure samples 
under ambient conditions with angular increments of 0.02˚ covering a 2θ range of 2 to 80˚. 
 
2.3. Stability of particles upon exposure to humidity 
To monitor the stability of the formulated particles, moisture sorption profiles were 
determined using a dynamic vapour sorption (DVS) analyser (DVS Intrinsic, Surface 
Measurement Systems Ltd., London, UK). Samples were exposed to two sorption-desorption 
cycles, from 0 to 90% relative humidity, at 25 ˚C.  
 
2.4. In vitro aerosolisation performance and lung deposition 
In order to assess the in vitro aerosolisation performance, the aerodynamic diameters of the 
particles were calculated after dispersion of particles using a next generation impactor (NGI) 
(Copley Scientific Limited, Nottingham, United Kingdom). A 5 mg of sample was placed 
inside a gelatin capsule (size 3) to be dispersed using an Aeroliser
®
 (Pharmaxis Ltd, Frenchs 
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Forest, Australia), at airflow of 60 L/min for a duration of 4 seconds. Particles were collected 
according to their aerodynamic diameter at 7 stages with cut-off points 8.06, 4.46, 2.82, 1.66, 
0.94, 0.55 and 0.34 microns when dispersed at 60 L/min (68). Then 5 ml of calcium chloride 
(CaCl2) 60% solution was used to dissolve the particles at each stages and 1 ml of each 
solution was used for quantification of fibroin using a UV-Vis spectrophotometer with max at 
274 nm (UV-1800, Shimadzu Corporation, Tokyo, Japan). A standard curve was generated in 
order to quantify the results. The fine particle fraction (FPF), the proportion of particles that 
are smaller than 5 µm in diameter from the emitted dose per actuation, was calculated using 
the proportion of the fine particle dose less than 5 µm in the total actuated dose in the 
impactor. 
 
3. Investigation for antibacterial action naturally exhibited by silk proteins 
3.1.  Preparation of silk samples 
Raw materials of silk were used for the disc diffusion assay, for fibroin and sericin from both 
AM and BM species. Silk stock solutions were each prepared at 1 mg/ml concentration and 
were diluted as required for each assay.  
 
3.2. Antimicrobial susceptibility testing 
3.2.1. Disc diffusion assay 
A Mueller-Hinton agar, containing 22 g of Mueller-Hinton broth (Sigma-Aldrich, Castle Hill, 
Australia) and 15 g of Agar in deionised water, was prepared to be poured into petri dishes at 
a depth of approximately 5 mm and were left overnight. Mueller-Hinton agar was used 
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instead of nutrient agar as per recommendations for antimicrobial susceptibility testing from 
Clinical and Laboratory Standard Institute (69). The agar surface was inoculated by using a 
swab dipped in a cell suspension adjusted to the turbidity of a 0.5 McFarland standard 
(approximately 10
6
 cells/ml). The three strains of bacteria were used were P.aeruginosa, 
S.aureus and E.coli. Sterilised paper discs filled with 25, 50 and 100 g of silk sample were 
placed on top of the inoculated agar. This experiment was carried out in triplicates. The plates 
were incubated overnight in air at 36˚C and the zone of inhibition was measured using a ruler. 
 
3.2.2.  Broth dilution assay 
Ten test tubes containing 5 ml of Mueller-Hinton broth were inoculated with Pseudomonas 
aeruginosa (P.aeruginosa), S.aureus or E.coli adjusted to the turbidity of a 0.5 McFarland 
standard (approximately 10
6
 cells/ml). AM and BM sericin and fibroin solutions were added 
to the test tubes each at ten different concentrations doubling from 0.098 µg/ml to 50 µg/ml. 
This experiment was carried out in duplicates. Incubation was done overnight in air at 36˚C 
and a visual inspection of turbidity was carried out for indication of bacteria growth, and 
minimum inhibitory concentration (MIC) was determined. 
 
3.2.3. Determination of minimum bactericidal concentration 
In order to determine the minimum bactericidal concentration (MBC), or whether the 
observed antibacterial activity was bacteriostatic or bactericidal, a 100 µl sample was taken 
out from each of the two tubes with no bacteria growth after treatment with silk protein 
solution from the broth dilution assay. The samples were each mixed with 5ml of sterile 
Mueller-Hinton broth in sterile test tubes. This experiment was carried out in duplicates. The 
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test tubes were incubated overnight in air at 36˚C and a visual inspection of turbidity was 
carried out for indication of bacteria growth. 
 
4. In vitro cytocompatibility of silk proteins and cytotoxicity of silk-cisplatin particles 
4.1. Cell culture and maintenance 
Human lung carcinoma epithelial cell line A549 was purchased from ATCC
®
. A549 cells are 
responsible for the diffusion of substances across the alveoli of lungs and thus it was used to 
investigate the cytocompatibility of silk and to assess cytotoxicity of silk particles loaded 
with cisplatin. Cells were maintained using ―normal media‖ consisting of Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 4500mg/L D-glucose, L-glutamine, with 10% 
foetal bovine serum (FBS), were used with 1% Penstrep
®
 or 1% antibiotic-antimycotic, as 
available (All from Gibco by Life Technologies, USA, except FBS from Sera Laboratories, 
UK). Cells were maintained at 37˚C in 95% air and 5% CO2 atmosphere. Medium was 
renewed every 2 to 3 days and passaged as needed when monolayer was 80-85% confluent. 
When passaging cells, the monolayer cells were washed with phosphate buffered saline 
(PBS), and were treated with TrypLE
TM
 Express (Gibco by Life Technologies, USA) or 
Trypsin/EDTA (Sigma-Aldrich, USA), as available, to detach the adherent cells. For 
trypsinisation process, enough trypsin was added to cover the cells (4 ml for T-75 flask), 
incubated for 2-3 minutes and visually checked for cell detachment by tapping the side of the 
flask and looking under the microscope. A small amount of media (2-3 ml) was added to stop 
the trypsinisation process and the cells were transferred to a 15 ml tube to be centrifuged at 
1500 rpm for 2 minutes. The supernatant was discarded and cells were resuspended in a 
desired volume of media to be transferred into a new flask. Mycoplasma testing was 
conducted twice for two separate batches of cells and results were negative at both times. All 
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polystyrene plastic flasks and plates used were of tissue culture grade. Each experiment was 
carried out in triplicates. 
 
4.2.  Preparation of samples for cell viability assays 
4.2.1. Formulation of two dimensional (2D) silk scaffolds using silk solutions 
2D silk scaffolds were formulated with the purpose to seed cells and culture on top of the 
scaffolds in order to test the cytocompatibility of silk proteins. AM and BM silk fibroin 
scaffolds and raw silk sericin powders were each dissolved in deionised water at desired 
concentrations, then were sterilised by filtering through 0.22 µm syringe filters (Millipore, 
Millex
®
 GP Filter Unit, Millipore Express PES Membrane). The silk solutions were used to 
cast 2D films on the 96-well plates, to be dried to form 2D silk scaffolds. These 2D silk 
fibroin scaffolds were treated with ethanol to induce insolubility by altering the structure of 
fibroin, as well as for sterilisation purposes. The scaffolds were washed three times with PBS 
and were sterilised with ultra-violet (UV) light for 30 minutes inside the biosafety cabinet, 
prior to seeding cells for cell viability assays. 
 
4.2.2. Preparation of silk conditioned media using formulated particles  
Samples were prepared using silk alone, silk + sugar (ratio 2:1), silk + mannitol + cisplatin 
(10:20:1), or silk + mannitol + cisplatin + genipin (10:20:1:1) formulations, dissolved at 
1mg/ml and 10mg/ml concentrations in normal media for 24 hours at 37˚C in the water bath. 
Sterilisation was done by filtering the sample dissolved in media through a syringe connected 
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to a 0.22 µm syringe filter (Millex
®
 GP Filter Unit, Millipore Express PES Membrane, 
Millipore, USA). 
 
4.3. Cell viability and proliferation assays 
For methyl thiazolyl tetrazolium (MTT; 3-(4,5-Dimethylthiazol-2yl)-2, 5-diphenyl 
tetrazolium bromide) and alamarBlue
®
 assays, cells were seeded on top of the 2D silk 
scaffolds (prepared as described in section 4.2.1), whereas Cell Counting Kit-8 (CCK-8) 
assay had cells seeded directly onto the tissue culture well plates then treated with silk-based 
particles dissolved in media (prepared as described in section 4.2.2).  
For each assay, A549 cells were seeded at a density of 2000 cells/well on 96-well plates, 
prepared in triplicates for each sample. Each well contained 100 µl media which was not 
renewed until the end of each experiment. For experiments with duration of seven days, small 
amounts of media (50 µl) were added to each well on the fourth day. 
 
4.3.1. AlamarBlue® cell viability assay 
Cells were seeded onto the 2D silk scaffolds and were monitored daily using a light 
microscope (Olympus CK40, Tokyo, Japan). Cells were maintained in normal maintenance 
conditions. At each predetermined time point, (days 1, 3, and 7), 10 µl of alamarBlue
®
 dye 
was added to each well and were incubated for 3 hours at 37ºC in the dark inside the 
incubator. Fluostar Optima plate reader (BMG Labtech, Ortenberg, Germany) was used at 
excitation 544 nm / emission 590 nm to measure fluorescence intensity. 
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4.3.2. MTT cell viability assay 
On the day of experiment, a stock solution of yellow tetrazole dye, MTT (Sigma-Aldrich, 
Castle Hill, Australia), was prepared by dissolving in deionised water to achieve 5 mg/ml 
concentration. This was stored in the dark at 4ºC. Cells were seeded onto the 2D silk 
scaffolds and were maintained in normal maintenance conditions. At each predetermined 
time point (days 0, 1, and 3), MTT solution was added (10 µl/well) and incubated for 3 hours 
at 37ºC in the dark, inside the incubator. After incubation, the formazon crystals were 
dissolved by adding 100 µl of isopropanol to each well, pipetting up and down, and using the 
plate shaker for 20 minutes. Optical density was measured spectrophotometrically at 570-690 
nm using an ELISA plate reader. 
4.3.3. CCK-8 cell viability assay 
Cells were seeded and were allowed to attach to the bottom of the wells (3-4 hours after 
seeding) before replacing normal media with conditioned media containing the particles 
(prepared as described in section 4.2.2). Cells were maintained in normal maintenance 
conditions. At each predetermined time point (days 1, 3 and 7), media was removed and cells 
were washed twice using sterile PBS. Fresh normal media (100 µl) was added to each well 
and placed back into the incubator. After one hour, 10 µl of CCK-8 reagent (Dojindo 
Molecular Technologies, Inc, Tokyo, Japan) was added to each well and was incubated for 2 
hours at 37ºC in the dark inside the incubator. The optical density (OD) of each well was 
measured using a microplate reader at 450 nm (Tecan Safire
2
, Switzerland). 
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4.4.  Picogreen® DNA quantification assay 
The DNA content in cells treated with various formulations was measured using a Picogreen
®
 
double-stranded DNA (dsDNA) Quantitation Kit (Invitrogen Molecular Probes, USA), 
according to the manufacturer’s protocol. Briefly, cells were seeded at 2000 cells/well in 96-
well plates and were allowed to attach with incubation in normal media. Cells were washed 
with sterile PBS and were incubated with filter-sterilised, conditioned media containing 1 
mg/ml of silk-alone, silk + sucrose (2:1), silk + mannitol + cisplatin (10:20:1), or silk + 
mannitol + cisplatin + genipin (10:20:1:1) (prepared as described previously in section 4.2.2).  
Picogreen
®
 assay was done after 24 and 72 hours of incubation. At each time point, cells 
were washed with PBS, detached using trypsin, and were resuspended in sterile water for cell 
lysis and release of DNA through freeze-thaw cycles repeated three times. Tris-
ethylenediamine-tetraacetic acid (TE) buffer was used to dilute the solution containing cells 
to a total volume of 500 µl, then Quant-iT
TM
 Picogreen
®
 reagent (Invitrogen Molecular 
Probes, USA) 0.5% in TE buffer was added to each sample. After incubation at room 
temperature in the dark for 5 minutes, 100 µl of each sample was transferred onto a black 96-
well plate in order to measure the fluorescence using Fluostar Optima plate reader (BMG 
Labtech, Ortenberg, Germany) at excitation 450 nm / emission 544 nm. Each experiment was 
carried out in triplicates. 
 
4.5. Changes in cell morphology 
Cells were seeded at a density of 2.5 x 10
5
 cells/well on a 24-well plate and were cultured for 
24 hours with normal media, and then normal media was replaced with filter-sterilised, 
conditioned media containing 1 mg/ml of silk-alone, silk + sugar (2:1), silk + mannitol + 
cisplatin (10:20:1), or silk + mannitol + cisplatin + genipin (10:20:1:1) (prepared as described 
50 
 
in section 4.2.2). Changes in cell morphology due to different treatment conditions were 
examined using light microscopy and immunofluorescence imaging. 
 
4.5.1.  Phase images 
Changes in cell morphology were observed using Olympus CK40 light microscope (Olympus, 
Tokyo, Japan) and phase images were taken using a transmitted light microscope (EVOS xl, 
Advanced Microscopy Group, Life Technologies, USA) with 10x and 20x magnifications at 
24 and 48 hours.  
 
4.5.2. Immunocytochemistry 
Immunocytochemistry was used to monitor changes in morphology and in the expression of 
gap junction protein (beta-catenin) in response to silk-based formulations.  
After 30 hours of incubation with conditioned media, media was removed and cells were 
washed twice using sterile PBS. Immunocytochemistry protocol from Abcam
®
 was used with 
some modifications (70). Briefly, cells were fixed in paraformaldehyde 4% in PBS (prepared 
from powder purchased from Sigma-Aldrich, USA) with 20 minutes incubation at room 
temperature, followed by washing twice with cold PBS. Cells were permeabilised in PBS 
containing 0.1% Triton X (BDH Laboratory Supplies, England) for 20 minutes, washed three 
times with PBS, 5 minutes per wash. Blocking agents used were bovine serum albumin (BSA) 
1% (Sigma-Aldrich, USA) or goat serum 5% (Invitrogen, Camarillo, CA, USA) in PBS, as 
available, for 30 minutes prior to incubation with primary antibody. Although BSA was 
known to be the most widely used blocking agent, the serum from the same animal species of 
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the secondary antibody was recommended to be used (82). Therefore, 5% goat serum was 
used as the blocking agent when available. 
Primary antibody anti-beta catenin, clone 7F7.2; IgG (Millipore, USA) was diluted at ratios 
of 1:100, 1:250, 1:500 or 1:1000 in PBS, incubated overnight at 4˚C covered with foil to 
prevent exposure to light. After incubation, the cells were washed with PBS. The 1:250 
dilution ratio was found to be appropriate for optimum staining, and this dilution ratio was 
used in all subsequent experiments. 
Secondary antibody Alexa Fluor
®
 555 containing 5 mM sodium azide (Life Technologies, 
USA) was diluted at 1:200 in PBS and incubated for one hour at room temperature in the 
dark. The cells were washed with PBS. Counter staining with conjugated F-actin 
(ActinGreen
TM
 488, Life Technologies, USA) diluted at 2 drops/ml in PBS was incubated in 
the dark for 30 minutes at room temperature. Cells were washed with PBS. DAPI (4',6-
Diamidino-2-Phenylindole, Dilactate) nucleus staining (Invitrogen Molecular Probes, USA) 
(diluted 1:2000 in PBS) followed with 5 minutes incubation, and then cells were washed and 
were imaged using a fluorescent microscope (Nikon Eclipse TE2000-U inverted microscope) 
at 20x magnification.  
All washes after each staining were done in the dark, three times in PBS, 5 minutes per wash. 
Secondary antibody and DAPI were purchased from Invitrogen Molecular Probes, USA. 
Fluorescent images were merged using ImageJ software program downloaded from 
http://imagej.nih.gov/ij/download.html accessed on 16/01/2014. 
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4.6.  Cell Metabolism 
Cell metabolism was evaluated by biochemistry analysis using the YSI 2700 Select 
Biochemistry Analyser (YSI Incorporated, Yellow Springs, USA). Samples of media were 
collected after 1, 3 and 7 days of incubation with A549 cells cultured with media containing 
silk alone, silk + sugar (2:1), silk + mannitol + cisplatin (10:20:1), or silk + mannitol + 
cisplatin + genipin (10:20:1:1) formulations. L-lactate and D-glucose levels in media were 
measured in g/L and were expressed in a single graph. 
 
4.7.  Cell Migration and Invasion 
Cell migration and invasion were analysed using transwell cell culture chambers (8 µm pore 
size, BD Biosciences, Australia). A549 cells were kept in low serum media (containing 1% 
FBS) for 24 hours then were trypsinised and resuspended in low serum medium and placed in 
the upper chamber of the transwell insert (50,000 cells/well). Conditioned media containing 
silk with or without cisplatin and genipin, were placed in the upper chamber for ―accelerated 
escape‖ and in the lower chamber for ―suppressed attraction‖ (as seen in Figure 9). 
Incubation was for 3 or 8 hours in a humidified atmosphere with 95% air and 5% CO2 at 
37˚C. Then cells were fixed with 4% paraformaldehyde, and were stained for 30 minutes 
using 2% crystal violet in 10% ethanol. The non-invasive cells in the upper chamber were 
removed by wiping with a cotton swab. Cells in the lower surface of the transwell insert 
which migrated through the pores were imaged using a transmitted light microscope (EVOS 
xl, Advanced Microscopy Group, Life Technologies, USA) at 10x magnification and the 
number of migrated cells were counted using ImageJ software. Average number of migrated 
cells per image were graphed and analysed. 
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Figure 9. A schematic diagram of the experiment design for cell migration assays per 
transwell; (a) ―accelerated escape‖ assay and (b) ―suppressed attraction‖ assay 
 
4.7.1. “Accelerated escape” 
For each transwell, 50,000 cells were seeded, incubated for one hour and then conditioned 
media containing silk alone, silk + mannitol + cisplatin (10:20:1) or silk + mannitol + 
cisplatin + genipin (10:20:1:1) at the concentration of 1 mg/ml in low serum media was 
added to the upper chamber and incubated for 8 hours. 
 
4.7.2. “Suppressed attraction” 
For each transwell, 50,000 cells were seeded, incubated for one hour and then conditioned 
media containing silk alone, silk + mannitol + cisplatin (10:20:1) or silk + mannitol + 
(a) 
 
 
 
 
 
 
 
 
(b) 
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cisplatin + genipin (10:20:1:1) at 1 mg/ml in normal media with 10% FBS was added to the 
lower chamber and incubated for 8 hours. 
 
4.8.  Cell wound repopulation assay 
Cells were seeded at a density of 2.5 x 10
5
 cells/well and cultured in normal media until 90% 
confluent. Then cells were incubated in low serum media (containing 1% FBS) for 24 hours 
prior to this assay. Silk-conditioned media were also prepared 24 hours prior to this assay (as 
described in section 4.2.2) and filter-sterilised immediately before adding to wells. A pipette 
tip (200 µl) was used to scratch a wound on the midline of the culture well. Wound 
repopulation was documented using a transmitted light microscope (EVOS xl, Advanced 
Microscopy Group) with 10x magnification at 0, 24, and 48 hours. ImageJ software program 
was used for quantitative analysis, to measure and compare the area of wound at each time 
points. 
 
4.9.  Statistical analysis 
All data were produced in triplicates (n = 3) for reproducibility. Data were analysed and 
presented as means ± standard deviation of samples, except when indicated as standard error 
of means. The differences between the experimental and control groups were analysed using 
one-way analysis of variance (ANOVA) test. A p-value less than 0.05 were indicated as 
having a statistically significant difference. 
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IV. Results and discussion 
 
1. Characterisation of silk-based particles  
1.1. Assessment of particle size and morphology 
1.1.1. Particle size analysis of spray dried silk-based particles 
Laser diffraction for geometrical size analysis for spray dried particles consisting of AM 
fibroin and BM fibroin showed that mass median diameter (D(0.5)), otherwise known as the 
average particle diameter by mass, were 7.03 µm and 5.20 µm respectively (Table 2). These 
formulations were suitable sizes for deposition in the lungs, as the particles 1 to 5 µm in 
diameter are capable of being deposited in the small airways and alveoli, while the particles 5 
to 10 µm in diameter are mainly deposited in the large airways (71).  
 
Table 3. Mean particle size (µm) of spray dried particles, as determined by laser diffraction 
analysis; shows mass median diameter (D(0.5)) for each formulation. Both AM and BM 
fibroin particles were produced at flow rate of 4.2 ml/min, atomiser 55 mbar, aspiration 100%, 
and inlet temperature 120 C; the table shows average of three experimental repeats ± 
standard deviation. 
 D(0.1) D(0.5) D(0.9) 
AM fibroin 2.89 ± 0.60 7.03 ± 0.19 15.28 ± 19.87 
BM fibroin 1.71 ± 0.09 5.20 ± 0.69 16.73 ± 5.73 
 
Spray dried silk fibroin particles observed from the SEM micrographs were between 0.5 µm 
and 10 µm in size, with most particles in the range of 2 µm to 4 µm (Figure 10).  
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Particle sizes varied according to different parameters used on the spray dryer, and the 
optimisation of inlet temperature, aspiration, atomisation flow and the feed rate of solution 
led to inhalable sizes of silk particles. An obvious reduction in size was observed when lower 
feed rates were used. Figures 10 (a) and (b) show the same batch of BM fibroin produced at a 
feed rate of 4.2 ml/min which resulted in similar in particle sizes, while (c) and (d) show two 
different batches of AM fibroin produced at feed rates of 1.7 ml/min and 4.2 ml/min 
respectively. Overall, particles were smaller when lower feed rates were used, especially for 
AM fibroin where the liquid feed rate of 1.7 ml/min was used (Figure 10 (c) & (d)). This 
demonstrated that the lower feed rates of silk solutions into the spray dryer produced smaller 
particles sizes. 
Also, higher atomisation flow and thus, the smaller droplets of silk solution led to smaller 
particles. This was explained by more energy being supplied to break up the liquid droplet 
into smaller droplets during the atomisation step (72).  
The AM and BM sericin solutions, which were spray dried using lower feed rates of 1.0 
ml/min, produced smaller particles (Figure 11). From the SEM micrographs, it can be seen 
that the particle sizes are smaller compared to fibroin particles observed previously and the 
majority of those particle sizes were around 1 to 5 m. Although it is known that higher feed 
rate produces better yields, lower feed rates were used in order to produce particle sizes less 
than 5 m to be suitable for potential delivery to the lower airways (72). 
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Figure 10. SEM micrographs of spray dried silk particles of: (a)(b) BM fibroin and (c)(d) 
AM fibroin produced using 2% (w/v) silk solutions; all batches were produced at a feed rate 
of 4.2 ml/min except (c) which was produced at 1.7 ml/min. All other parameters were 
consistent: atomiser 55 mbar, aspiration 100%, and inlet temperature 120 C. 
 
 
   
Figure 11. SEM micrographs of spray dried BM sericin (left) and AM sericin (right) 
produced using the following parameters: feed rate of 1.0 ml/min, atomiser 55 mbar, 
aspiration 100%, and inlet temperature 120 C 
  
(a)                                                             (b)  
(c)                                                              (d)  
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1.1.2. Particle size analysis of spray-freeze-dried particles 
Particle sizes assessed by observing the SEM micrographs highlighted that the spray-freeze-
dried particles were larger than the spray dried silk-based particles. The size distributions of 
spray-freeze-dried formulations containing trehalose and mannitol as lyoprotectants, 
measured using dynamic light scattering, revealed significantly larger geometrical particle 
sizes compared to spray dried particles. The average particle diameter by mass (D(0.5)) of 
triplicated samples averaged 22.75 µm and 10.08 µm for spray-freeze-dried silk + mannitol + 
cisplatin and silk + mannitol + cisplatin + genipin formulations respectively (Figure 12 (a) 
and (b)). It can be seen that the crosslinking of fibroin lowered the average particle size and 
broadened the particle size distribution. Porous polymeric microparticles for inhalation are 
required to have diameters between 5 and 30 μm and are able to achieve high aerosolisation 
efficiency as a consequence of reduced particle density (73). Therefore these cisplatin-
containing silk-based particles showed potential for aerosolisation and lung deposition.  
 
The spray-freeze-dried fibroin particles containing sucrose could not be measured using 
dynamic light scattering due to agglomeration and the inability to be dispersed. The 
formulation containing trehalose as a lyoprotectant was able to be dispersed. However, the 
result showed a bimodal distribution of particle size with most particles in the range of 10 to 
30 m or around 1 mm. The peak showing the larger particles on Figure 12 (c) is likely to 
represent the agglomerated particles and not single particles, therefore, trehalose was an 
inferior lyoprotectant compared to mannitol in achieving suitable particle sizes for pulmonary 
delivery (Figure 12 (c)). 
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Figure 12. Particle size distributions for spray-freeze-dried: (a) silk + mannitol + cisplatin, (b) 
silk + mannitol + cisplatin + genipin and (c) silk + trehalose formulations; the samples were 
triplicated, as represented by the three colours in each panel. 
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1.2. Morphology  
1.2.1. The morphology of spray dried particles 
(a) Silk fibroin formulations, with no drug incorporated 
From the particles that had burst open, it was demonstrated that spray-dried particles were 
spherical and hollow (Figure 10 (d)). The ruptured or collapsed particles observed on the 
SEM micrographs were the result of the spherical and hollow particles being unable to 
maintain their shape in the high vacuum used during the process of imaging. This confirmed 
that there were empty spaces inside the spray dried particles. 
The surfaces of these particles were rough, rugged and irregular as seen in the height retraced 
AFM images in Figure 13. Since the roughness or corrugation of the particles play an 
important role in aerosolisation performance, these particles showed potential for successful 
lung deposition.  
   
Figure 13. AFM images showing topography of spray-dried BM (left) and AM (right) silk 
fibroin particles; used scan rate 0.30 Hz and 0.4 Hz and scan size 600 nm and 1.5 µm, 
respectively  
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(b) Silk fibroin formulations, containing antibiotics 
The silk particles containing antibiotics, regardless of ciprofloxacin and gentamicin, were 
agglomerated overall as can be seen from the SEM micrographs in Figure 14. The surface of 
the particles containing antibiotics were more wrinkled compared to particles spray dried 
with silk alone as presented previously in Figure 10. The AM fibroin formulation containing 
ciprofloxacin as seen in Figure 14 (a), consisted of small amounts of larger particles with 
smooth surfaces and appeared to have a more wide particle size distribution. The formulation 
containing gentamicin and BM fibroin with ciprofloxacin had more uniform sizes overall and 
wrinkled surfaces on majority of the particles as can be seen in Figure 14 (b) and (c). 
 
           
Figure 14. SEM micrographs portraying silk as carriers of drugs; (a) spray dried AM fibroin 
0.5% + ciprofloxacin 0.1%, (b) spray dried AM fibroin 0.5% + gentamicin 0.1%, (c) spray 
dried BM fibroin 0.7% + ciprofloxacin 0.07% 
 
1.2.2. The morphology of spray-freeze-dried particles 
(a) Silk fibroin formulations, with no drug incorporated 
The SEM micrographs of spray-freeze-dried particles of BM fibroin, with sucrose as 
lyoprotectant, showed that the particles were spherical and porous (Figure 15). The particles 
were ―fluffy‖, agglomerated and could neither be dispersed for laser diffraction particle size 
analysis nor for testing lung deposition using the next generation impactor. These qualities 
(a)                                                (b)                                               (c) 
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made the BM fibroin formulation difficult to handle and therefore an alternative lyoprotectant 
(trehloase or mannitol) needed to be chosen. 
 
   
Figure 15. Spray-freeze-dried BM fibroin with sucrose as a lyoprotectant; silk:sucrose ratio 
was 2:1 (the scale for both images are as indicated on the right) 
 
The morphology observed from the above SEM micrographs correlated well with the AFM 
images in Figure 16, showing the topography of the same batch of spray-freeze-dried BM 
fibroin particles formulated with sucrose. The topography of particles was more uniform 
between the particles within the same batch, compared to the spray dried particles. The spray-
freeze-dried particles were larger and porous bearing characteristics which were favourable to 
achieving good aerosolisation performance. The aerodynamic size (da) for spherical particles 
was varied according to the particle density as well as the geometric diameter (dg), as shown 
in the following equation: 
 
where p is the mass density of the particle and  p0 is the unit standard particle density (1 
g/cm
3
) (49). Therefore, despite the particles having larger diameters in spray-freeze-dried  
formulations due to their porosity and low densities, they can also have suitable aerodynamic 
sizes for potential successful deposition in the lower airways (74).  
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Figure 16. A three-dimensional AFM image of spray-freeze-dried BM fibroin formulated 
with sucrose as a lyoprotectant with silk to sucrose ratio 2:1, scan rate 0.4 Hz and scan size 
10.24 µm  
 
(b) Silk fibroin formulations containing cisplatin 
The SEM micrographs of silk fibroin with trehalose together with cisplatin can be seen in 
Figure 17. Most particles appeared to be uniformly mixed, although backscattering SEM 
micrographs may show better compositional differences between the batches of particles.  
The SEM micrographs in Figure 18 show silk fibroin and cisplatin at different concentration 
ratios. BM fibroin and trehalose concentrations were kept constant both at 0.5% and the 
concentration of cisplatin was varied (0.5%, 0.1%, 0.05%). However, the morphological 
differences between the formulations observed from the SEM micrographs were minimal. 
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Figure 17. SEM micrographs of BM fibroin 1% mannitol 0.75% cisplatin 0.2% 
 
    
Figure 18. Spray freeze-dried silk-cisplatin particles with trehalose used as a lyoprotectant. 
Ratio of silk fibroin to cisplatin were (a) 1:1, (b) 5:1 and (c) 10:1 
 
(c) Silk fibroin cross-linked with genipin loaded with cisplatin 
The formulations with fibroin cross-linked with genipin prior to loading cisplatin are shown 
in SEM images in Figure 19. Some minor changes in the morphology were observed as a 
result of crosslinking with genipin. There were some obvious changes such as particles 
appearing to be more porous, however, the spherical shape was maintained in most particles 
and the level of agglomeration between the particles was similar to the non-crosslinked silk-
based particles.  
 
(a)                                               (b)                                             (c) 
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Figure 19. SEM micrographs of formulations of silk cross-linked with genipin; BM fibroin 
0.5% + mannitol 1% + cisplatin 0.05% + genipin 0.05% 
 
 
1.3. The effect of lyoprotectant on formulation of particles  
Trehalose was the chosen lyoprotectant to be used in place of sucrose in order to achieve 
better dispersion and aerosolisation efficiency. In order to determine the optimum ratio of silk 
fibroin to trehalose, ratios of 1:1, 2:1 or 1:2 at various concentrations of BM fibroin to 
trehalose were used. The best combination for ideal morphology, as seen on the SEM 
micrographs, was found to be BM fibroin 0.5% with trehalose 0.5% (Figure 20 (d) and (e)). 
The particles in this particular formulation were porous yet spherical, and had approximate 
diameters between 5 and 20 µm. 
However, when AM fibroin was spray-freeze-dried with trehalose as a lyoprotectant, the 
particles produced were hygroscopic and absorbed moisture immediately upon contact with 
water. Some of the particles ―melted‖ upon contact with air as they absorbed water and 
disappeared. The remaining trehalose-containing particles were characterised using SEM to 
reveal the disappearance of single particles in Figure 21. Clumps of particles were formed as 
the single particles were connected to each other, which also explain the reason for much 
larger particle sizes observed in Figure 12 (c). The exact stage of the formulation process 
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where there was morphological change cannot be identified. However, it was assumed that 
the breakdown of the single particle structures may have occurred during the drying process 
in the freeze dryer. As both batches of AM fibroin were affected appeared to ―melt‖, when 
spray-freeze-dried with trehalose as a lyoprotectant, this is likely to demonstrate an 
incompatibility between the AM fibroin and trehalose. For the subsequent formulations, only 
BM fibroin was used for this project, and trehalose was considered an unsuitable 
lyoprotectant for silk-based particles in this project. 
As such, mannitol was used as an alternative lyoprotectant in this project. Formulations using 
various concentration ratios of BM fibroin and mannitol were used, and the optimum ratio of 
BM fibroin to mannitol was found to be 1:2 respectively, which required more sugar 
(mannitol) in order to maintain the shape and morphology of the particles (Figure 22). For the 
case of the 1:1 ratio, the morphology of the particles was not uniform, with only a distinct 
number of particles having spherical shape. The particle sizes in the 1:2 ratio of the above 
formulation were larger with average particle diameters between 10 and 30 µm, and showed 
potential aerosolisation due to the porous nature of the particles. 
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Figure 20. The effect of trehalose concentration on morphology of BM fibroin / trehalose 
particles compared at concentrations of: (a) 0.1% / 0.1%, (b) 0.5% / 0.25%, (c) 0.5%/1%, 
(d)(e) 0.5% / 0.5% 
 
   
Figure 21. Spray-freeze-dried AM fibroin particles with trehalose as a lyoprotectant; (a) AM 
fibroin 1% trehalose 1% and (b) AM fibroin 0.5% trehalose 0.5% cisplatin 0.1% 
 
(d)                                                              (e)  
(a)                                              (b)                                              (c)  
(a)                                                             (b)  
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Figure 22. Spray-freeze-dried BM fibroin containing mannitol as lyoprotectant, loaded with 
cisplatin: (a)(b) BM fibroin 0.5% mannitol 0.5% cisplatin 0.1%, (c)(d) BM fibroin 0.5% 
mannitol 1% cisplatin 0.1%  
 
1.4. Structure of particles and determination of crystallinity 
The spray-freeze-dried BM fibroin 1% + sucrose 0.5% and BM fibroin 0.5% + trehalose 0.5% 
were analysed for crystallinity and both formulations were found to be amorphous (Figure 
23). When mannitol was used as the lyoprotectant, the x-ray diffractogram of the 
formulations revealed sharp peaks that represented crystalline structures, regardless of the 
presence of cisplatin and genipin (Figure 24). The x-ray diffractograms for spray-freeze-dried 
formulations of silk + mannitol + cisplatin with or without genipin were observed to be the 
same as that of spray-freeze-dried silk + mannitol. Therefore, the same x-ray diffractogram 
was obtained for the above formulations, which have been presented as one graph in Figure 
24.  
(a)                                                             (b)  
(c)                                                             (d)  
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Figure 23. X-ray diffractograms showing amorphous structures for spray-freeze-dried 
particles: (a) BM fibroin 1% + sucrose 0.5% and (b) BM fibroin 0.5% + trehalose 0.5%; with 
angular increments of 0.02˚ covering a 2θ range of 2 to 80˚ 
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Figure 24. X-ray diffractogram showing crystalline structures for spray-freeze-dried BM 
fibroin 0.5% + mannitol 1%; with angular increments of 0.02˚ covering a 2θ range of 2 to 80˚ 
 
R
el
a
ti
v
e 
in
te
n
si
ty
 
0              10                  20                 30                  40                  50                 60                 70                 80  
2θ (Degrees) 
(a) 
 
 
 
(b) 
70 
 
1.5. Stability of particles upon exposure to humidity 
Due to the possible instability in the spray-freeze-dried BM fibroin formulation containing 
trehalose as a lyoprotectant, it was necessary to determine its moisture sorption profile using 
a DVS analyser (Figure 25). The change in the mass isotherm plot shows evidence of 
particles being unstable, indicating that the particles retain moisture when exposed to 
humidity especially in the second cycle. The moisture uptake reached a maximum of 50.98% 
at a relative humidity of 90%. Another peak in the change in mass was observed towards the 
end of the second cycle, which represented particles being unstable to moisture. However, the 
reasons or mechanisms behind this phenomenon remain subject to further investigation.  
In contrast, the spray-freeze-dried BM fibroin formulation containing mannitol as a 
lyoprotectant was shown to be more stable compared to the formulation containing trehalose. 
The mass isotherm plot in Figure 25 shows that the second desorption cycle does not have a 
sudden change in mass, and the change in mass is more regulated, which demonstrated better 
stability in response to humidity compared to the formulation containing trehalose. 
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Figure 25. Moisture sorption isotherms for spray-freeze-dried BM fibroin with trehalose (top) 
and spray-freeze-dried BM fibroin with mannitol (bottom) 
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2. Investigation for antibacterial effects exhibited in natural silk proteins 
2.1. Screening for presence of antibacterial activities 
This assay qualitatively showed that one sample, BM sericin, had an antibacterial action 
against S.aureus as demonstrated by the clear zones around the discs treated with BM sericin 
solution that represented no growth of bacteria. The average zones of inhibition were 
measured to be 14 mm, 17 mm and 22 mm for 25 µg, 50 µg and 100 µg of BM sericin 
respectively, as shown in Figure 26.  
 
Figure 26. A S.aureus-inoculated Mueller-Hinton agar plate showing the zones of inhibition 
of BM sericin from the disc diffusion assay (the same zones were measured for the triplicated 
samples) 
 
2.2. Determination of minimum inhibitory concentration 
From the broth dilution assay, all test tubes excluding two test tubes containing Mueller-
Hinton broth inoculated with S.aureus and treated with BM sericin were turbid, which 
indicated bacteria growth overnight. The concentrations of BM sericin in the two test tubes 
were 25 and 50 µg/ml. Therefore, the MIC of BM sericin against S.aureus was determined to 
be 25 µg/ml.  
22 mm 
17 mm 14 mm 
Negative 
control 
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2.3. Assessment of the antibacterial activity 
All samples tested for MBC were turbid, which indicated growth of bacteria overnight. This 
demonstrated that the antibacterial activity previously observed with BM sericin against 
S.aureus was bacteriostatic, instead of being bactericidal. 
 
2.4. Conclusion and future studies 
It was desired that silk drug delivery systems work synergistically with the incorporated anti-
infective drug to combat infections. There were triplicated results that demonstrated positive 
antimicrobial action naturally exhibited by BM sericin, as presented above from the first disc 
diffusion assay and the broth dilution assay. However, the same results were unable to be 
replicated in subsequent experiments. Therefore, from these experiments, silk proteins cannot 
be concluded as exhibiting natural antibacterial actions. 
Some hypothesis for the inability to reproduce the results were that there may be 
contamination in the samples that led to components other than silk protein, for example, the 
pesticides used while culturing the silk cocoons, to be responsible for the antimicrobial effect 
observed. Another hypothesis was that there was variability between the batches of processed 
silk proteins that led to only some batches having antimicrobial activity. In order to test these 
hypotheses in future studies, a gel electrophoresis could be conducted for every batch of 
samples received. However, it was not done for the purpose of this thesis, since the focus was 
on the formulation of silk proteins for use as a drug delivery vehicle. 
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3.  Particle dispersibility and in vitro testing for deposition in the lungs 
3.1. Dispersion of spray dried particles for in vitro lung deposition 
The spray dried particles were found to be dispersed with almost no particles retained in the 
capsule inside an Aeroliser
® 
inhaler device, after it was subject to airflow of 60 L/min for the 
duration of 4 seconds. The fine particle fraction (FPF), the proportion of particles with 
aerodynamic diameter less than 5 µm, was calculated to be 61.67% (Figure 27).  
 
 
Figure 27. Cumulative mass fraction for spray dried BM fibroin particles, showing the fine 
particle fraction (FPF) of particles less than 5 µm in diameter; tested in vitro at airflow 
60L/min for 4 seconds using a next generation impactor 
 
3.2. Dispersion of spray-freeze-dried particles for in vitro lung deposition 
The FPF of spray-freeze-dried BM fibroin with trehalose used as a lyoprotectant was 
calculated to be 62.25% (Figure 28). This was similar to spray dried BM fibroin particles that 
had FPF of 61.67%. These results showed that silk-based particles had high efficiency of 
aerosolisation, comparable or higher than those dry powder inhaler formulations currently on 
the market, including Seretide
TM
 and Symbicort
TM
 (75-77).  
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The above formulations were regarded as having successful in vitro lung deposition, 
compared to spray-freeze-dried fibroin with sucrose used as lyoprotectant. The FPF for 
spray-freeze-dried BM fibroin with sucrose was unable to be determined, as the majority of 
the particles were retained inside the capsule and could not be dispersed for in vitro testing. 
This was obvious from the difficulty in handling the powder as they were ―sticky‖ and 
agglomerated (the SEM micrograph for this formulation is presented in Figure 15). 
 
 
Figure 28. Cumulative mass fraction for spray-freeze-dried particles of BM fibroin 0.5% 
with trehalose 0.5%, showing the fine particle fraction (FPF) of particles less than 5 µm in 
diameter; tested in vitro at airflow 60L/min for 4 seconds using a next generation impactor 
 
Due to the similarities in particle size and morphology between the drug-loaded and non-
loaded spray-freeze-dried silk particles, aerosolisation performance was not investigated for 
the silk particles loaded with cisplatin. The conditions used in the production of particles in 
spray-freeze-drying were the same for both the drug-loaded and silk alone particles, and 
similar particle size and morphology were observed. Consequently, it is anticipated that the 
dispersion and aerosolisation performance would be comparable to the above presented data. 
 
 
FPF = 62.25%  
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4. In vitro cytotoxicity assays of silk-based particles 
4.1. Introduction 
Cytocompatibility and toxicity for formulations containing silk alone, silk with lyoprotectant, 
and silk carrier loaded with cisplatin, were evaluated using various in vitro assays.  
MTT, CCK-8 and alamarBlue
®
 assays were used to compare cell viability and proliferation in 
the presence of silk protein with or without cisplatin to control group (no treatment). All 
assays were quantitative colorimetric assays and varied slightly in their mechanism of action; 
however each assay had their unique advantages, which are outlined below. 
The MTT assay measured the cellular viability and mitochondrial activity of viable cells, by 
the formation of formazan dye generated by the activities of dehydrogenases in viable cells 
upon incubation with the MTT reagent. The CCK-8 assay was also based on the amount of 
formazan dye, but was more convenient and accurate as the CCK-8 reagent contains a highly 
water-soluble tetrazolium salt that automatically solubilises in the media, which eliminated 
the need to solubilise the formazan crystals, which was necessary for the MTT assay (78). 
The alamarBlue
®
 is a highly sensitive assay that measures the metabolic activity as the 
oxidation-reduction indicator inside the reagent fluoresces and changes colour in response to 
cellular metabolic reduction (79, 80). A distinct advantage of the alamarBlue
® 
assay was that 
the reagent is minimally toxic to living cells, therefore the same well plate could be carried 
on to do subsequent readings at different time points. Thus alamarBlue
®
 assay allows for the 
least seeding error or plate-to-plate variability.  
Both MTT and alamarBlue
®
 assays were used to evaluate lung cell viability in the presence 
of raw silk proteins in this project. The CCK-8 assay was used to evaluate cell viability in the 
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presence of silk-based particles in media or pre-conditioned media containing silk-based 
particles with or without cisplatin delivered via normal or cross-linked silk formulations. 
Other assays to support the data for cell viability assay results included in this thesis were 
measurements for cell metabolism and DNA quantification, along with cell migration and 
invasion, and wound repopulation assays. Phase and fluorescent microscopy were used to 
analyse changes in morphology of cells growing in the presence of the silk-based 
formulations, and are presented in this chapter. 
 
4.2. Cell Viability Assays 
Cells were exposed to treatments by having silk-based particles dissolved inside the media 
maintaining the cells, or cells were seeded on top of 2D silk scaffolds. The patterns of cell 
growths in these two methods were comparable. The purpose of the 2D scaffolds of silk 
proteins in both alamarBlue
®
 and MTT assays was to investigate the cytocompatibility of silk 
proteins, solely from the contact between the cell and silk proteins, without the influence of 
the size, shape, surface energy or other properties of the particles. CCK-8 assay was used to 
determine the cytocompatibility of silk-based carriers and cytotoxicity of the formulations 
with silk-based carriers delivering cisplatin. 
Similarities in cell proliferation were demonstrated for most 2D silk scaffold samples – 
across all fibroin and sericin from both AM and BM species (Figure 29 & 30). The cells 
proliferated in a normal manner in the presence of silk proteins and all types of silk proteins 
were cytocompatible, especially until day 3, where there were no statistical differences 
observed for both alamarBlue
®
 and MTT assays (Figure 29 & 30). There were more 
variances in cell proliferation when alamarBlue
®
 assay was carried on until day 7 (Figure 29). 
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This was an expected result, as the media combined with AM and BM silk fibroin showed 
increased viscosity and formed a gel structure upon culturing for this extended period. 
Results of the one-way ANOVA statistical analysis and Bonferroni’s multiple comparisons 
test for the data from alamarBlue
®
 assay proved that the differences in cell growth for AM 
and BM fibroins compared to control were statistically significant. Both AM and BM sericin 
at both 0.1% and 1% concentrations showed no significant difference in cell growth over the 
seven days of experiment, except AM sericin had significantly higher proliferation on day 7 
compared to control.  
Since the formation of gel structure in media was observed for the alamarBlue
®
 assay, MTT 
assay was carried out for a duration of three days, using three separate well plates. There 
were significant differences in cell proliferation between control and most samples on day 1, 
however no significant differences were observed on day 3 (Figure 30). The reason for this 
could be that the cells seeded on the 2D silk films were proliferating at a slower rate and later 
at a similar rate to cells growing on tissue culture plate (control). Other reasons for this result 
could due to seeding error or plate-to-plate variability, taking into account that there were 
separate well plates set up for each time point (due to the design of the experiment, since 
MTT reagent is toxic and could not carry on multiple time points using one well plate as 
alamarBlue
®
 assay). 
Overall, the proliferation of cells on 2D silk scaffolds closely mimicked that of control, and 
thus both silk fibroin and sericin were considered to be cytocompatible with A549 cells. 
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Figure 29. Results of alamarBlue
®
 assay showing cell growth on two-dimensional silk 
scaffolds of two concentrations 0.1% and 1%. Seeding density was 2000 cells/well. Data are 
expressed as mean ± standard deviation and one-way ANOVA statistical analysis was used. 
AmF = AM fibroin, BmF = BM fibroin, AmS = AM sericin, BmS = BM sericin 
 
Figure 30. Results of MTT assay showing cell growth on 2D silk scaffolds of two 
concentrations 0.1% and 1%. Seeding density was 2000 cells/well. Data are expressed as 
mean ± standard deviation and one-way ANOVA statistical analysis was used. AmF = AM 
fibroin, BmF = BM fibroin, AmS = AM sericin, BmS = BM sericin 
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The cytocompatibility of silk fibroin alone was also proved from the CCK-8 assay, with silk 
alone and silk + sucrose proliferating in a similar manner to control, as shown in Figure 31. 
One-way ANOVA statistical analysis at each time point showed that differences in cell 
proliferation existed between the control and silk alone on days 3 and 7, while the cells 
treated with the formulation containing sucrose as lyoprotectant showed significant difference 
only on day 3 and no difference in proliferation on day 7 compared to control. The other two 
samples in CCK-8 assays, cisplatin-containing formulations with or without crosslinking of 
silk using genipin showed statistically significant suppression of growth of cells from day 1 
and more cells were dead by day 3 as can be seen in Figure 31. The cytotoxic effect was 
maintained until day 7 and was considered that the cisplatin was effectively carried and 
delivered to the cancer cells by the silk-based particles formulated in this project.  
 
  
Figure  31. Results of CCK-8 assay: Cell proliferation with media containing silk fibroin ± 
sugar (Man = mannitol) ± cisplatin (Cisp) ± genipin (Gen) measured on days 1, 3 and 7. 
Concentration of particles used was 1mg/ml (w/v) for all samples; data are expressed as mean 
± standard deviation and one-way ANOVA statistical analysis was used. 
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Due to the higher proliferation of cancer cells observed in response to the silk-sucrose 
formulations compared to the formulation containing silk alone, the effect of concentration of 
sugar used as lyoprotectant in the cisplatin-containing formulations were tested. The 
cytotoxicity of cisplatin in ―high sugar‖ formulation (silk + mannitol + cisplatin ratio 10:20:1) 
and ―low sugar‖ formulation (silk + mannitol + cisplatin ratio 10:8:1) were compared at 
overall particle concentrations of 1 mg/ml and 10 mg/ml and results are presented in Figure 
32. There were no significant differences in day 1 across all formulations, however one-way 
ANOVA statistical differences were observed in all formulations compared to control from 
the second day. The cytotoxicity of cisplatin did not differ significantly according to sugar 
content in 10 mg/ml overall concentration however the effect of high concentration of 
mannitol superseded the cytotoxicity of cisplatin in 1 mg/ml and reached a statistically 
significant difference on days 2 and 7. Therefore the cytotoxic effect of cisplatin was 
analysed to be affected by sugar content only when the concentration of cisplatin itself was 
low. Nevertheless, it is recommended that future studies have alternative method of 
formulating these particles, in order to eliminate or reduce the sugar content in order to 
evaluate the cytotoxicity of cisplatin carried by silk particles. 
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Figure 32. Comparison between formulations of silk fibroin + cisplatin 1mg/ml or 10mg/ml 
with high or low mannitol concentrations; data are expressed as mean ± standard error of 
mean and one-way ANOVA statistical analysis was used. 
 
The comparison of cell viabilities between normal silk + cisplatin and cross-linked silk + 
cisplatin formulations for both 1 mg/ml and 10 mg/ml concentrations are shown in Figure 33. 
The differences observed were more obvious and statistically significant in the 1 mg/ml 
formulations. The cross-linked silk + cisplatin formulation had significantly higher cytotoxic 
effect than the normal silk + cisplatin formulation at 1 mg/ml concentrations. The differences 
between the cytotoxicity of normal silk + cisplatin 10 mg/ml and cross-linked silk + cisplatin 
1mg/ml were not significant across the seven days according to one-way ANOVA statistical 
analysis at each time point. This demonstrated that a similar level of cytotoxicity is achieved 
even at one-tenth concentration of cisplatin, when it is delivered via cross-linked silk carrier. 
This result highlighted the benefits of using cross-linked fibroin over normal fibroin as 
carriers for cisplatin. 
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Figure 33. Comparison between formulations of Silk + Cisp (silk + mannitol + cisplatin; 
10:20:1) or Silk (cross-linked) + Cisp (silk + mannitol + cisplatin + genipin; 10:20:1:1) at 
1mg/ml or 10 mg/ml concentrations; data are expressed as mean ± standard error of mean and 
one-way ANOVA statistical analysis was used. 
 
4.3. Double strand DNA content (Picogreen® assay) 
The results from cell viability assays were confirmed by DNA content assay using the 
Picogreen
®
 assay. As seen in Figure 34, the DNA content was comparable across all 
conditions on the first day after the treatment, and then clear differences were observed after 
3 days of incubation. It was obvious that silk alone or silk + sugar has similar number of cells 
to the control group, and that cells treated with cisplatin had minimal changes in DNA 
content from day 1 to day 3. These results were consistent with the results from the cell 
viability assays. 
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Figure 34. Quantification of DNA contents purified from A549 cells cultured in the presence 
of 1mg/ml of silk alone, silk + sucrose (2:1), silk + mannitol + cisplatin (10:20:1), silk + 
mannitol + cisplatin (10:20:1:1) formulations, or control (no treatment); data are expressed as 
mean ± standard deviation and one-way ANOVA statistical analysis was used. 
  
4.4. Changes in cell morphology with silk-based treatment 
The morphology of A549 cells treated with silk and silk + sugar particles were very similar to 
cells in normal media with no treatment, and supported the data obtained from the cell 
viability assays (Figure 35). In Figure 36, the similarities were observed on the images 
obtained from fluorescent microscopy, and this clearly demonstrated that the silk was 
compatible to A549 cells, and that cells grown in the presence of silk-based particles 
proliferated in a similar way to the cells grown in normal media. When sugar was added to 
the spray-freeze-dried formulations as a lyoprotectant, it enhanced the growth of cells as the 
sugar was an energy source for the cells to grow (81). This was observed from the phase 
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images in Figure 35, where cells proliferated and had grown on top of each other in a similar 
way to control group, as they became over-confluent in the presence of silk and sugar. 
 
(a) Control                             (b) Silk alone                        (c) Silk + sugar 
 
 
Figure 35. Similar morphology can be observed for (a) Control (b) Silk alone (c) Silk + sugar, 
at 24 hours and 48 hours of treatment 
 
 
 
 
 
 
 
Figure 36. Similarities in morphology of control and silk-treated cells, stained F-actin (green), 
beta-catenin (red) and DAPI (blue) 
 
(a) Control                                      (b) Silk alone                                (c) Silk + sugar 
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For the cells treated with cisplatin, obvious reductions in the number of living and attached 
cells were observed, and also distinct morphological differences for those surviving cells 
were observed in contrast to control group (Figure 37). There was a significantly less number 
of living cells in the formulation that had silk cross-linked with genipin. Despite the same 
concentrations of cisplatin incorporated in the normal and cross-linked silk formulations, it 
was observed that the cross-linked silk formulations had stronger cytotoxicity (Figure 37 (c)). 
The sizes of the surviving cells were also different; the cells that received no treatment 
(control) had average perimeters of 106.68 µm whereas the cisplatin-containing normal and 
cross-linked silk-based particles led to cells having average perimeters of 175.24 µm and 
205.15 µm respectively, after 48 hours of treatment with conditioned media (Figure 38). One-
way ANOVA statistical analysis showed statistically significant differences in the cell sizes 
compared to control for the cells treated with silk + mannitol + cisplatin formulation at both 
24 and 48 hours. However the cross-linked silk had significant effect in cell size only at 48 
hours and not 24 hours. The enlargement of cells were indicative of senescence-like cells, 
where they are metabolically active but has lost the function to divide, as a result of being 
treated with cisplatin. The delayed significant enlargement of cells treated with cisplatin 
delivered via cross-linked silk was interpreted as the delay in the cytotoxicity of cisplatin 
delivered using cross-linked silk. 
The effect of this silk + mannitol + cisplatin + genipin formulation was remarkably evident in 
the reduced number of cells, change in the shape of surviving cells and presence of 
senescence-like cells as observed in the enlarged actin in Figure 39 (e). Figure 39 (d) and (e) 
showed significantly less number of nuclei (shown in blue; stained with DAPI) after 48 hours 
of treatment with cisplatin compared to control and silk-treated cells in (a), (b) and (c), which 
indicated that there were less number of living cells. 
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Figure 37. Morphological differences of A549 cells after 24 and 48 hours of treatment with 
silk-based cisplatin particles, with different impacts for normal and cross-linked silk 
formulations. Formulations used were Control (normal media), Silk + Cisplatin (silk + 
mannitol + cisplatin 10:20:1), or Silk (cross-linked) + Cisp (silk + mannitol + cisplatin + 
genipin 10:20:1:1), each at 1mg/ml concentration 
 
 
Figure 38. The conditioned media with different formulations have varying effects on the 
average size of the cells. * indicates significant difference in cell size to control group; data 
are expressed as mean ± standard deviation and one-way ANOVA statistical analysis was 
used for statistical significance. 
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Figure 39. Immunofluorescence images after 48 hours of treatment with (a) normal media 
(control) (b) silk alone, (c) silk + sugar, (d) silk + mannitol + cisplatin 10:20:1 and (e) silk + 
mannitol + cisplatin + genipin 10:20:1:1. Stained with F-actin (green) and DAPI (green) 
 
4.5. Cell Metabolism (YSI) 
The glucose concentration decreased by 1.5 g/L in the culture medium for control (no 
treatment), from 4.17 ± 0.09 g/L to 2.67 ± 0.19 g/L after seven days (Figure 40). The 
treatment with silk alone showed similar results with glucose concentration changed by 1.45 
g/L from 5.16 ± 0.51 g/L to 3.71 ± 0.35 g/L after seven days of experiment.  
In contrast, there were minor changes in the glucose concentration for the medium with cells 
treated with cisplatin delivered via normal or cross-linked silk, decreasing only by 0.76 g/L 
and 0.39 g/L respectively, after seven days. This reflected that there were certainly less 
number of cells that are metabolically active and thus had subsequently reduced glucose 
uptake from the media, which supported the results from the CCK-8 cell viability assay. 
            (d) Silk + Cisplatin                (e) Silk (cross-linked) + Cisplatin 
(a) Control                                      (b) Silk alone                                (c) Silk + Sucrose 
89 
 
Similarly, there was no significant lactate release over the seven days for cells treated with 
both normal and cross-linked silk based formulations (Figure 40). This finding also supported 
the data from cell viability assays, as lactate is produced by mammalian cells as a metabolite 
by-product during the process while glucose is utilised for energy production (81). The 
increases in lactate concentration in media for silk alone and silk + sugar treated cells were 
similar to the increase observed in the control group, which represented cell proliferation over 
time. 
 
 
Figure 40. Cell metabolism: Increasing lactate levels and decreasing glucose levels detected 
in media as cells proliferate during incubation with silk ± cisplatin formulations. Data are 
expressed as mean ± standard error of mean. 
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4.6. Cell Migration and Invasion 
In ―Accelerated escape‖, differences in cell migration were not distinguished, except between 
control group and other treatment groups (Figure 41). It was desired for the cells treated with 
silk alone to stay in the upper chamber rather than migrating away from silk-containing 
media to the lower chamber containing high serum, to mimic the control group. However, it 
was observed that the cells treated with silk only migrated in a similar manner to silk + 
mannitol + cisplatin formulations. The cisplatin delivered via cross-linked silk did not have a 
significant difference in cell migration compared to cisplatin delivered via normal silk, when 
analysed by one-way ANOVA statistical analysis. 
When the particles were placed in the lower chamber to measure the suppressed movement of 
the cells from the upper chamber to the lower chamber (―suppressed attraction‖), the results 
were more closer to the hypothesis compared to the results of the first design of this 
experiment (―accelerated migration‖). The cells moved from upper chamber to the lower 
chamber containing silk favourably, while less number of cells migrated when cisplatin was 
present in the lower chamber (Figure 42). However, there were no significant differences 
observed in the cisplatin delivered via cross-linked or normal silk. The differences in cell 
responses may be greater if the formulation is modified, possibly by using a higher 
concentration of genipin for cross-linking or by altering the cross-linking time.  
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Figure 41. Average number of cells migrated over 8 hours from low serum media containing 
silk alone, silk + mannitol + cisplatin (Silk + Cisp) or silk+ mannitol + cisplatin + genipin 
(Silk (cross-linked) + Cisp) particles to high serum media (―Accelerated escape‖) * indicates 
significant difference compared to control (p<0.05), as analysed using one-way ANOVA; 
data are expressed as mean ± standard deviation. 
 
 
Figure 42. Average number of cells migrated over 8 hours from low serum media to high 
serum media containing particles ("Suppressed Attraction") Particles were added to the 
bottom chamber, each at concentrations of 1mg/ml. * indicates significant difference 
compared to control (p<0.05), as analysed using one-way ANOVA; data are expressed as 
mean ± standard deviation. 
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4.7. Wound repopulation assay 
At 48 hours after replacing media, the area of the wounds were almost completely closed by 
the cells treated with normal media and media containing silk regardless of the presence of 
sugar. In contrast, the wounds remained unclosed for those treated with cisplatin. As seen in 
Figure 43, the cells treated with formulations with silk alone or silk with sugar had 
repopulated and closed the wound in a similar manner to control. The cells treated with 
cisplatin-containing normal or cross-linked silk formulations did not repopulate and instead, 
the cytotoxic treatment had detached and killed the cells that were attached on the tissue 
culture plate (Figure 44).  
The extent of repopulation was quantified by measuring the area of the unclosed wound at 24 
hours. Figure 45 demonstrates that the percentage of wound area repopulated for cross-linked 
silk + cisplatin formulation was much lower than the other groups. Both the silk alone and 
silk with sugar had approximately 80% of wound area repopulated after 24 hours of treatment. 
One-way ANOVA statistical analysis revealed that the statistically significant differences in 
wound closure occurred only between control and the formulation with cross-linked silk (silk 
+ mannitol + cisplatin + genipin). The results from this assay again highlighted that the 
cytotoxic effect of cisplatin is more potent when it is delivered to the cells via cross-linked 
silk particles. 
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Figure 43. Wound repopulation assay. The ―wound‖ created using a pipette tip in the middle 
of a confluent monolayer of cells, was repopulated and the gap is closed for cells treated with 
silk alone and silk + sucrose (2:1) formulation, whereas the gap remained unclosed for cells 
treated with silk + mannitol (Man) + cisplatin (Cisp) (10:20:1) and silk + mannitol (Man) + 
cisplatin (Cisp) + genipin (Gen) (10:20:1:1) formulation. 
 
 
 
 
 
 
 
 
Figure 44. Phase images of cells treated with silk + mannitol + cisplatin + genipin (10:20:1:1) 
formulation after 48 hours of incubation, before (left) and after (right) washing with PBS to 
wash away detached or dead cells 
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Figure 45. Percentage of wound closed after 24 hours incubation with silk alone, silk + 
sucrose (2:1) formulation, silk + mannitol (Man) + cisplatin (Cisp) (10:20:1) and silk + 
mannitol (Man) + cisplatin (Cisp) + genipin (Gen) (10:20:1:1) formulations. Data are 
expressed as mean ± standard deviation and one-way ANOVA statistical analysis was used. 
 
4.8. Conclusion and need for further studies 
From the above results and discussions, it can be concluded that silk fibroin alone is 
cytocompatible, and that A549 lung cells can grow and proliferate on top of the 2D silk 
scaffolds as well as in the presence of silk particles dispersed in media.  
The presence of mannitol or other sugars used as lyoprotectants that were included during the 
spray-freeze-drying process may have diminished the cytotoxic effects of cisplatin in some 
formulations. It would be of benefit if particles were formulated using an alternative method 
in the future, without the need of sugar, so that the effects of silk and cisplatin could be 
distinguished and more specific conclusions could be drawn. 
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95 
 
The above cell viability assays using A549 cell monolayers were sufficient to draw 
conclusions for the purpose of this thesis; however it is imperative that new lung models are 
designed in future studies to advance the experiments for cytotoxicity studies. Growing three 
dimensional (3D) lung cancer cells, in contrast to growing in 2D monolayers, would mimic 
the biology of the human lung cancer development more closely and may contribute to the 
advances in treatment for lung cancer (41).
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V. Conclusions and Future Work 
Silk particles have been formulated to act as efficient carriers of drugs with a focus on 
delivering drugs targeted for lung delivery. Cisplatin was successfully incorporated into silk 
drug carriers and this project demonstrated potential to deliver cisplatin directly to the lungs 
via dry powder inhalers instead of the conventional injection method. The aerosolisation 
performance of the particles demonstrated the ability for adequate dispersion and reaching 
down to the lower airways. These inhalable silk fibroin particles were found to be 
cytocompatible with lung cells. These lung cells showed normal growth and proliferation in 
the presence of silk proteins in the media. 
The hypothesis that silk proteins naturally exhibit antibacterial activity was not confirmed or 
rejected in this thesis due to an inability to generate reproducible data, possibly related to 
variability of silk materials supplied for this project. 
However, the silk carriers were loaded with an anticancer drug, cisplatin, to be formulated for 
targeted delivery to the lungs. The formulation was optimised for particle size, morphology 
and stability to be suitable for pulmonary delivery. Silk fibroin was cross-linked with genipin 
for a modified release of cisplatin, and the formulation was shown to have more cytotoxic 
effect compared to immediate release of cisplatin. This demonstrated that the cross-linked 
silk formulations delivered cisplatin in such a way that had more potent cytotoxic effects.  
Cisplatin on its own was not tested as a treatment group due to the focus of this project being 
on silk being used as a drug carrier. The given time frame of this project did not allow the 
extra time to design sterilisation methods for cisplatin or for optimisation of dosage of 
cisplatin tested. Many previous studies have demonstrated the cytotoxic responses of A549 
cells to cisplatin alone, for example a study by Zhang et al (2003) tested the cytotoxicity of 
cisplatin alone and compared with the combination with another anticancer drug Gleevec 
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using MTT assay (82). More recent examples are studies by Kim et al (2006) and Zhang et al 
(2014), in search for ways to enhance chemosensitivity of A549 cells toward cisplatin (83, 
84). Nevertheless, future studies may include a positive control, cisplatin alone, in order to 
compare the cytotoxicity of cisplatin alone and cisplatin released from the silk-based particles. 
It is recommended also that future studies have alternative method of formulating these silk-
based particles, in order to eliminate or reduce the presence of sugar used as lyoprotectants in 
the spray-freeze-dried formulations. Although it was demonstrated that the sugar content did 
not alter the cytotoxicity of the cisplatin according to sugar content in 10 mg/ml overall 
concentration, the sugar may have contributed to proliferation of cells generally.  
Further studies may include a drug release study and investigation of rate of release with the 
resultant cytotoxic effects. Different levels of crosslinking of silk fibroin may be achieved by 
using various concentrations of genipin and altering the time of crosslinking. The differences 
in cytotoxicity between cisplatin released from cross-linked silk or normal silk microparticles 
were not as significant as expected in this project. The differences in cell responses may be 
greater if the formulation is modified, possibly by using a higher concentration of genipin for 
cross-linking or by altering the cross-linking time. 
Degradation studies of silk fibroin, especially in an environment that mimics the lungs can be 
conducted to use results to estimate suitable doses of silk fibroin that could be administered 
for subjects in future animal studies, if feasible. 
Overall, optimised formulations of silk-based drug carriers have been demonstrated to be 
cytocompatible and had efficient aerosolisation for potential application in controlled release 
cisplatin treatment in lung cancer. 
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